JP5512067B2 - Skin cosmetics - Google Patents
Skin cosmetics Download PDFInfo
- Publication number
- JP5512067B2 JP5512067B2 JP2005352733A JP2005352733A JP5512067B2 JP 5512067 B2 JP5512067 B2 JP 5512067B2 JP 2005352733 A JP2005352733 A JP 2005352733A JP 2005352733 A JP2005352733 A JP 2005352733A JP 5512067 B2 JP5512067 B2 JP 5512067B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- tenninka
- action
- inhibitory action
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002537 cosmetic Substances 0.000 title claims description 26
- 239000000284 extract Substances 0.000 claims description 119
- 239000003795 chemical substances by application Substances 0.000 claims description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 239000000203 mixture Substances 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 17
- 239000003960 organic solvent Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 description 81
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 57
- 239000000523 sample Substances 0.000 description 44
- 210000003491 skin Anatomy 0.000 description 40
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 34
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 34
- 229940095074 cyclic amp Drugs 0.000 description 34
- 238000000605 extraction Methods 0.000 description 34
- 238000004519 manufacturing process Methods 0.000 description 34
- 238000002835 absorbance Methods 0.000 description 31
- 102000002268 Hexosaminidases Human genes 0.000 description 29
- 108010000540 Hexosaminidases Proteins 0.000 description 29
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 28
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 28
- 210000002950 fibroblast Anatomy 0.000 description 28
- 108010003272 Hyaluronate lyase Proteins 0.000 description 27
- 102000001974 Hyaluronidases Human genes 0.000 description 27
- 229960002773 hyaluronidase Drugs 0.000 description 27
- 102000003425 Tyrosinase Human genes 0.000 description 25
- 108060008724 Tyrosinase Proteins 0.000 description 25
- 230000009471 action Effects 0.000 description 25
- 230000035755 proliferation Effects 0.000 description 25
- 230000002087 whitening effect Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 230000003712 anti-aging effect Effects 0.000 description 23
- 235000013399 edible fruits Nutrition 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 230000001076 estrogenic effect Effects 0.000 description 22
- 230000001737 promoting effect Effects 0.000 description 21
- 239000002260 anti-inflammatory agent Substances 0.000 description 20
- 229940121363 anti-inflammatory agent Drugs 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 19
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 18
- 230000002849 elastaseinhibitory effect Effects 0.000 description 18
- 235000013305 food Nutrition 0.000 description 18
- 239000012488 sample solution Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- -1 lipolysis promoters Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 240000008620 Fagopyrum esculentum Species 0.000 description 5
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 5
- 102000016387 Pancreatic elastase Human genes 0.000 description 5
- 108010067372 Pancreatic elastase Proteins 0.000 description 5
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 230000003796 beauty Effects 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- OMRLTNCLYHKQCK-KSTCHIGDSA-N 4-nitrophenyl N-acetyl-alpha-D-glucosaminide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 OMRLTNCLYHKQCK-KSTCHIGDSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 201000011152 Pemphigus Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 201000001976 pemphigus vulgaris Diseases 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 208000010247 contact dermatitis Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 244000062730 Melissa officinalis Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 240000007994 Rhodomyrtus tomentosa Species 0.000 description 2
- 235000007234 Rhodomyrtus tomentosa Nutrition 0.000 description 2
- 241000219995 Wisteria Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 235000015094 jam Nutrition 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 235000012045 salad Nutrition 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- GVUGADOWXGKRAE-SRVKXCTJSA-N 4-[[(2s)-1-[[(2s)-1-[[(2s)-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GVUGADOWXGKRAE-SRVKXCTJSA-N 0.000 description 1
- AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229940122393 Hyaluronidase inhibitor Drugs 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001237745 Salamis Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229940008396 carrot extract Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 108010006161 conchiolin Proteins 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- YZSJUQIFYHUSKU-UHFFFAOYSA-N ethanol;propane-1,2-diol Chemical compound CCO.CC(O)CO YZSJUQIFYHUSKU-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- YLLIGHVCTUPGEH-UHFFFAOYSA-M potassium;ethanol;hydroxide Chemical compound [OH-].[K+].CCO YLLIGHVCTUPGEH-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000015175 salami Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤、サイクリックＡＭＰホスホジエステラーゼ阻害剤、皮膚化粧料及び美容用飲食品に関するものである。 The present invention relates to an anti-inflammatory agent, a whitening agent, a tyrosinase inhibitor, an anti-aging agent, a slimming agent, a cyclic AMP phosphodiesterase inhibitor, a skin cosmetic, and a cosmetic food and drink.
炎症性の疾患、例えば接触性皮膚炎（かぶれ）、乾癬、尋常性天疱瘡、その他肌荒れに伴う各種皮膚疾患等の原因や発症機構は多種多様であるが、その原因としてヒアルロニダーゼ、ヒスタミン、ヘキソサミニダーゼ等によるものが知られている。 There are various causes and onset mechanisms of inflammatory diseases such as contact dermatitis (rash), psoriasis, pemphigus vulgaris, and various other skin diseases associated with rough skin, including hyaluronidase, histamine, and hexosa. The thing by minidase etc. is known.
生体組織への親和性を保つヒアルロン酸塩は、含水系の中で紫外線や酵素等によって分解され、分子量の低下に伴って保水効果も減少する。また、ヒアルロン酸は細胞間組織中に存在し、血管透過性とも関与している。さらに、肥満細胞中に存在し、活性化されたヒアルロニダーゼ塩は、肥満細胞からの脱顆粒に関与しているといわれている。したがって、ヒアルロン酸の加水分解酵素であるヒアルロニダーゼの活性を阻害することにより、ヒアルロン酸の安定化を図り、肥満細胞からの種々のケミカルメディエーターの放出を防ぐことができるとともに、保湿の強化、接触性皮膚炎（かぶれ）、乾癬、尋常性天疱瘡、その他肌荒れに伴う各種皮膚疾患等、様々な炎症性疾患の予防、治療又は改善に効果があるものと考えられる。 Hyaluronate that maintains affinity for living tissue is decomposed by ultraviolet rays, enzymes, and the like in a water-containing system, and the water retention effect decreases with a decrease in molecular weight. Hyaluronic acid is present in intercellular tissues and is also involved in vascular permeability. Furthermore, the activated hyaluronidase salt present in mast cells is said to be involved in degranulation from mast cells. Therefore, by inhibiting the activity of hyaluronidase, which is a hydrolase of hyaluronic acid, it can stabilize hyaluronic acid and prevent the release of various chemical mediators from mast cells. It is considered to be effective in preventing, treating or improving various inflammatory diseases such as dermatitis (rash), psoriasis, pemphigus vulgaris, and various other skin diseases associated with rough skin.
このような考えに基づき、ヒアルロニダーゼ阻害作用を有するものとしては、例えば、オスベッキア属に属する植物の抽出物（特許文献１参照）、藤茶抽出物（特許文献２参照）、ローズマリー、タイム及びメリッサ抽出物（特許文献３参照）等が知られている。 Based on such an idea, as a substance having a hyaluronidase inhibitory action, for example, an extract of a plant belonging to the genus Osbecchia (see Patent Document 1), a wisteria tea extract (see Patent Document 2), rosemary, thyme and melissa Extracts (see Patent Document 3) and the like are known.
また、ヒスタミンは、マストセル内に存在し、脱顆粒反応により放出されたものが起炎物質として作用する。細胞内のヒスタミンが遊離されると同時にヘキソサミニダーゼも遊離されることから、ヘキソサミニダーゼの遊離を指標にヒスタミン遊離抑制作用を評価することができる。したがって、ヘキソサミニダーゼの遊離を抑制することにより、同時にヒスタミンの遊離も抑制でき、これにより接触性皮膚炎（かぶれ）、乾癬、尋常性天疱瘡、その他肌荒れに伴う各種皮膚疾患等、様々な炎症性疾患等の予防、治療又は改善に効果があるものと考えられる。 Histamine is present in the mast cell, and the substance released by the degranulation reaction acts as a flammable substance. Since histamine in the cells is released and hexosaminidase is released at the same time, histamine release inhibitory action can be evaluated using hexosaminidase release as an index. Therefore, by inhibiting the release of hexosaminidase, it is also possible to inhibit the release of histamine at the same time, thereby causing various skin diseases such as contact dermatitis (rash), psoriasis, pemphigus vulgaris, and other rough skin. It is considered effective for prevention, treatment or improvement of inflammatory diseases.
このような考えに基づき、ヘキソサミニダーゼ遊離抑制作用を有するものとしては、例えば、紅雪茶抽出物（特許文献４参照）等が知られている。 Based on such an idea, for example, red snow tea extract (see Patent Document 4) is known as one having a hexosaminidase release inhibitory action.
皮膚においてメラニンは、紫外線から生体を保護する役目も果たしているが、過剰生成や不均一な蓄積は、皮膚の黒化やシミの原因となる。一般にメラニンは、色素細胞の中で生合成される酵素チロシナーゼの働きによって、チロシンからドーパ、ドーパからドーパキノンに変化し、ついで５，６−ジヒドロキシインドフェノール等の中間体を経て形成されるものとされている。したがって、皮膚の色黒（皮膚色素沈着症）、シミ、ソバカス等を予防、治療又は改善するためには、メラニンの産生に関与するチロシナーゼの活性を阻害することが考えられる。 Melanin also plays a role in protecting the body from ultraviolet rays in the skin, but overproduction and uneven accumulation cause skin darkening and spots. In general, melanin is converted from tyrosine to dopa and from dopa to dopaquinone by the action of the enzyme tyrosinase biosynthesized in pigment cells, and then formed through intermediates such as 5,6-dihydroxyindophenol. ing. Therefore, in order to prevent, treat or improve skin darkness (skin pigmentation), spots, buckwheat, etc., it is conceivable to inhibit the activity of tyrosinase involved in the production of melanin.
従来、皮膚色素沈着症、シミ、ソバカス等の予防、治療又は改善には、ハイドロキノン等の化学合成品を有効成分とする美白剤を外用する処置が行われてきた。しかしながら、ハイドロキノン等の化学合成品は、皮膚刺激、アレルギー等の副作用のおそれがある。そこで、安全性の高い天然原料を有効成分とする美白剤の開発が望まれており、チロシナーゼ阻害作用を有するものとしては、例えば、藤茶抽出物（特許文献５参照）、ヤナギタデ抽出物（特許文献６参照）等が知られている。 Conventionally, for the prevention, treatment or improvement of skin pigmentation, stains, buckwheat, etc., a treatment using a whitening agent containing a chemically synthesized product such as hydroquinone as an active ingredient has been performed. However, chemically synthesized products such as hydroquinone may cause side effects such as skin irritation and allergies. Therefore, it is desired to develop a whitening agent containing a highly safe natural raw material as an active ingredient. Examples of those having a tyrosinase inhibitory action include wisteria tea extract (see Patent Document 5), willow extract (patent Reference 6) is known.
加齢に伴う皮膚老化の一因は、女性ホルモンの一種であるエストロゲンの分泌が減退することにある。すなわち、エストロゲンは成人女性の健康維持に深く関わっており、その分泌不足は種々の内科的疾患を招くほか、肌の過敏症、弾力性の低下、潤いの減少等、好ましくない肌の変化の原因となることが知られている。 One cause of skin aging with aging is a decrease in the secretion of estrogen, a female hormone. In other words, estrogen is deeply involved in maintaining the health of adult women, and its lack of secretion leads to various medical illnesses, as well as causes of unfavorable skin changes such as skin hypersensitivity, reduced elasticity, reduced moisture, etc. It is known that
そこで、エストロゲンの分泌が衰える更年期以降の女性に対して、エストロゲンと同様の作用を有する物質を配合した薬剤を、経皮的又は経口的に投与することが行われている。このようなエストロゲン様作用を有するものとしては、例えば、五斂子の葉部からの抽出物（特許文献７参照）等が知られている。 Therefore, a drug containing a substance having the same action as estrogen is transdermally or orally administered to women after menopause, whose estrogen secretion declines. As such an estrogen-like action, for example, an extract from the leaves of quince (see Patent Document 7) is known.
皮膚の表皮及び真皮は、表皮細胞、線維芽細胞、及びこれらの細胞の外にあって皮膚構造を支持するコラーゲン等の細胞外マトリックスにより構成されている。若い皮膚においては線維芽細胞の増殖は活発であり、線維芽細胞、コラーゲン等の皮膚組織の相互作用により皮膚に水分が保持されるとともに、皮膚の柔軟性、弾力性等が確保され、皮膚は外見的にも張りや艶があってみずみずしい状態に維持される。 The epidermis and dermis of the skin are composed of epidermal cells, fibroblasts, and an extracellular matrix such as collagen that is outside these cells and supports the skin structure. In young skin, the proliferation of fibroblasts is active, and moisture is retained in the skin by the interaction of skin tissues such as fibroblasts and collagen, and the flexibility and elasticity of the skin are secured. It is maintained in a fresh state with its tension and gloss.
ところが、紫外線、空気の著しい乾燥、過度の皮膚洗浄等、ある種の外的因子の影響があったり、加齢が進んだりすると線維芽細胞の増殖が遅くなり皮膚の保湿機能や弾力性が低下する。そして、皮膚は張りや艶を失い、荒れ、シワ等の老化症状を呈するようになる。そのため、線維芽細胞の増殖を促進することにより皮膚の老化を予防又は改善することができると考えられる。このような考えに基づき、線維芽細胞増殖促進作用を有するものとしては、例えば、クスノハガシワ抽出物（特許文献８参照）等が知られている。 However, the growth of fibroblasts slows down due to the influence of certain external factors such as ultraviolet rays, drastic drying of air, excessive skin washing, etc., and aging progresses, and the moisture retention function and elasticity of the skin decrease. To do. And the skin loses its tension and gloss, and exhibits aging symptoms such as roughness and wrinkles. Therefore, it is considered that aging of the skin can be prevented or improved by promoting the proliferation of fibroblasts. Based on such an idea, as a substance having a fibroblast proliferation promoting action, for example, Kusunohagashi extract (see Patent Document 8) is known.
近年、飽食や運動不足等の生活習慣が原因となって体脂肪が増加し、肥満が増えている。このような肥満の増加は、人間ばかりでなく、ペットや家畜においても見られる。肥満は、高脂血症や動脈硬化等の成人病の原因になるため、美容の面で問題となるばかりでなく、健康の面でも大きな問題となる。 In recent years, body fat has increased due to lifestyle habits such as satiety and lack of exercise, and obesity has increased. Such an increase in obesity is seen not only in humans but also in pets and livestock. Obesity is a cause of adult diseases such as hyperlipidemia and arteriosclerosis, which is not only a cosmetic problem but also a major problem in health.
生体内の脂肪を分解するためには、サイクリックＡＭＰの役割が重要となる。サイクリックＡＭＰは生体内に存在するリパーゼを活性化し、活性化されたリパーゼによって脂肪が脂肪酸とグリセロールとに分解される。しかし、サイクリックＡＭＰホスホジエステラーゼが活性化されるとサイクリックＡＭＰの分解が誘発され、リパーゼの活性化が阻害される。そのため、サイクリックＡＭＰホスホジエステラーゼの活性を阻害することにより細胞内におけるサイクリックＡＭＰが増量し、脂肪の分解を促進することができるものと考えられる。このような考えに基づき、サイクリックＡＭＰホスホジエステラーゼ阻害作用を有するものとしては、例えば、ピーナッツ渋皮抽出物（特許文献９参照）等が知られている。
本発明は第一に、安全性の高い天然物の中からヒアルロニダーゼ阻害作用及び／又はヘキソサミニダーゼ遊離抑制作用を有するものを見出し、それを有効成分とする抗炎症剤を提供することを目的とする。 A first object of the present invention is to find a highly safe natural product having a hyaluronidase inhibitory action and / or a hexosaminidase release inhibitory action, and to provide an anti-inflammatory agent comprising the active ingredient as an active ingredient. And
本発明は第二に、安全性の高い天然物の中からチロシナーゼ阻害作用を有するものを見出し、それを有効成分とする美白剤又はチロシナーゼ阻害剤を提供することを目的とする。 The second object of the present invention is to find a natural product having a tyrosinase inhibitory action among highly safe natural products, and to provide a whitening agent or a tyrosinase inhibitor containing the same as an active ingredient.
本発明は第三に、安全性の高い天然物の中からエラスターゼ阻害作用、エストロゲン様作用及び線維芽細胞増殖促進作用からなる群より選ばれる１種又は２種以上の作用を有するものを見出し、それを有効成分とする抗老化剤を提供することを目的とする。 Thirdly, the present invention finds one having at least one action selected from the group consisting of an elastase inhibitory action, an estrogen-like action and a fibroblast proliferation promoting action among highly safe natural products, It aims at providing the anti-aging agent which uses it as an active ingredient.
本発明は第四に、安全性の高い天然物の中からサイクリックＡＭＰホスホジエステラーゼ阻害作用を有するものを見出し、それを有効成分とするスリミング剤又はサイクリックＡＭＰホスホジエステラーゼ阻害剤を提供することを目的とする。 A fourth object of the present invention is to find a highly safe natural product having a cyclic AMP phosphodiesterase inhibitory action, and to provide a slimming agent or a cyclic AMP phosphodiesterase inhibitor containing the same as an active ingredient. To do.
本発明は第五に、安全性の高い天然物の中から、ヒアルロニダーゼ阻害作用、ヘキソサミニダーゼ遊離抑制作用、チロシナーゼ阻害作用、エラスターゼ阻害作用、エストロゲン様作用、線維芽細胞増殖促進作用及びサイクリックＡＭＰホスホジエステラーゼ阻害作用からなる群より選ばれる１種又は２種以上の作用を有するものを見出し、それを配合した皮膚化粧料又は美容用飲食品を提供することを目的とする。 Fifth, among the highly safe natural products, the present invention includes hyaluronidase inhibitory action, hexosaminidase release inhibitory action, tyrosinase inhibitory action, elastase inhibitory action, estrogen-like action, fibroblast proliferation promoting action and cyclic An object of the present invention is to find one having at least one action selected from the group consisting of AMP phosphodiesterase inhibitory action, and to provide a skin cosmetic or cosmetic food or drink containing the same.
上記課題を解決するため、本発明の抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤及びサイクリックＡＭＰホスホジエステラーゼ阻害剤は、テンニンカからの抽出物を有効成分として含有することを特徴とし、また、本発明の皮膚化粧料及び美容用飲食品は、テンニンカからの抽出物を配合したことを特徴とする。 In order to solve the above-mentioned problems, the anti-inflammatory agent, whitening agent, tyrosinase inhibitor, anti-aging agent, slimming agent and cyclic AMP phosphodiesterase inhibitor of the present invention contain an extract from tenninka as an active ingredient. In addition, the skin cosmetics and beauty foods and beverages of the present invention are characterized by blending an extract from tenninka.
本発明の抗炎症剤においては、上記抽出物が、ヒアルロニダーゼ阻害作用及び／又はヘキソサミニダーゼ遊離抑制作用を有することが好ましく、本発明の抗老化剤においては、上記抽出物が、エラスターゼ阻害作用、エストロゲン様作用及び線維芽細胞増殖促進作用からなる群より選ばれる１種又は２種以上の作用を有することが好ましい。 In the anti-inflammatory agent of the present invention, the extract preferably has a hyaluronidase inhibitory action and / or hexosaminidase release inhibitory action. In the anti-aging agent of the invention, the extract has an elastase inhibitory action. It preferably has one or more actions selected from the group consisting of an estrogen-like action and a fibroblast proliferation promoting action.
本発明によれば、天然物であるテンニンカからの抽出物を有効成分として含有し、安全性に優れた抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤、サイクリックＡＭＰホスホジエステラーゼ阻害剤、皮膚化粧料又は美容用飲食品を提供することができる。 According to the present invention, an anti-inflammatory agent, a whitening agent, a tyrosinase inhibitor, an anti-aging agent, a slimming agent, cyclic AMP phosphodiesterase inhibition, which contains an extract from natural tenninka as an active ingredient and is excellent in safety. An agent, skin cosmetic, or beauty food or drink can be provided.
以下、本発明について説明する。
〔抗炎症剤，美白剤，チロシナーゼ阻害剤，抗老化剤，スリミング剤，サイクリックＡＭＰホスホジエステラーゼ阻害剤〕
本発明の抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤又はサイクリックＡＭＰホスホジエステラーゼ阻害剤は、テンニンカからの抽出物を有効成分として含有する。
The present invention will be described below.
[Anti-inflammatory agent, whitening agent, tyrosinase inhibitor, anti-aging agent, slimming agent, cyclic AMP phosphodiesterase inhibitor]
The anti-inflammatory agent, whitening agent, tyrosinase inhibitor, anti-aging agent, slimming agent or cyclic AMP phosphodiesterase inhibitor of the present invention contains an extract from tenninka as an active ingredient.
ここで「スリミング」とは、痩身作用のことを意味し、痩身作用としては、例えば、生体内に蓄積された脂肪細胞の分解を促進する作用や、生体内への脂肪細胞の蓄積を抑制する作用等が挙げられるが、これらの作用に限定されるものではない。したがって、本明細書において「スリミング剤」とは、肥満を予防、治療又は改善することのできる抗肥満剤を意味し、スリミング剤には、例えば、痩身剤、脂肪分解促進剤、脂肪蓄積抑制剤等が含まれる。 Here, “slimming” means a slimming action. As the slimming action, for example, the action of promoting the degradation of fat cells accumulated in the living body or the accumulation of fat cells in the living body are suppressed. Although an effect etc. are mentioned, it is not limited to these actions. Therefore, in the present specification, the “slimming agent” means an anti-obesity agent that can prevent, treat or ameliorate obesity, and the slimming agent includes, for example, slimming agents, lipolysis promoters, fat accumulation inhibitors. Etc. are included.
また、本発明において「テンニンカからの抽出物」には、テンニンカを抽出原料として得られる抽出液、当該抽出液の希釈液若しくは濃縮液、当該抽出液を乾燥して得られる乾燥物、又はこれらの粗精製物若しくは精製物のいずれもが含まれる。 In the present invention, the “extract from Tenninka” includes an extract obtained from Tenninka as an extraction raw material, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, or these Either a crude product or a purified product is included.
本発明において使用する抽出原料は、テンニンカ（学名：Rhodomyrtus tomentosa (Ait.) Hassk.）である。
テンニンカ（Rhodomyrtus tomentosa (Ait.) Hassk.）は、東南アジアの熱帯から亜熱帯域等の地域に分布しているフトモモ科に属する常緑低木であり、日本では沖縄等に自生しており、これらの地域から容易に入手することができる。テンニンカの果実は、生食されるほかジュースやジャムの原料にも使用されている。また中国では桃金娘と呼ばれ、果実は民間的に妊婦の貧血、止血剤として、また、葉や根も民間的に頭痛、腹痛等の治療等に使用されている。
The extraction raw material used in the present invention is tenninka (scientific name: Rhodomyrtus tomentosa (Ait.) Hassk.).
Tenninka (Rhodomyrtus tomentosa (Ait.) Hassk.) Is an evergreen shrub belonging to the family Myrtaceae distributed in the tropical and subtropical regions of Southeast Asia. In Japan, it grows naturally in Okinawa, etc. It can be easily obtained. Tenninka fruit is used as raw material for juice and jam in addition to being eaten raw. In China, it is called Momokin daughter, and the fruit is privately used as anemia and hemostatic agent for pregnant women, and the leaves and roots are privately used for the treatment of headache and abdominal pain.
抽出原料として使用し得るテンニンカの構成部位としては、例えば、葉部、枝部、樹皮部、幹部、茎部、果実部、花部等の地上部、根部又はこれらの部位の混合物等が挙げられるが、好ましくは地上部、根部若しくは果実部、又はこれらの部位の混合物である。 Examples of the constituent parts of the tenninka that can be used as the raw material for extraction include above-ground parts such as leaves, branches, barks, trunks, stems, fruits, and flower parts, roots, or mixtures of these parts. Is preferably the above-ground part, root part or fruit part, or a mixture of these parts.
テンニンカからの抽出物に含有されるヒアルロニダーゼ阻害作用、ヘキソサミニダーゼ遊離抑制作用、チロシナーゼ阻害作用、エラスターゼ阻害作用、エストロゲン様作用、線維芽細胞増殖促進作用又はサイクリックＡＭＰホスホジエステラーゼ阻害作用を有する物質の詳細は不明であるが、植物の抽出に一般に用いられている抽出方法によって、テンニンカからこれらの作用を有する抽出物を得ることができる。 Of hyaluronidase inhibitory action, hexosaminidase release inhibitory action, tyrosinase inhibitory action, elastase inhibitory action, estrogen-like action, fibroblast proliferation promoting action or cyclic AMP phosphodiesterase inhibitory action contained in extracts from Tenninka Although details are unknown, extracts having these actions can be obtained from tenninka by an extraction method generally used for plant extraction.
例えば、上記植物を乾燥した後、そのまま又は粗砕機を用いて粉砕し、抽出溶媒による抽出に供することにより、ヒアルロニダーゼ阻害作用、ヘキソサミニダーゼ遊離抑制作用、チロシナーゼ阻害作用、エラスターゼ阻害作用、エストロゲン様作用、線維芽細胞増殖促進作用又はサイクリックＡＭＰホスホジエステラーゼ阻害作用を有する抽出物を得ることができる。乾燥は天日で行ってもよいし、通常使用される乾燥機を用いて行ってもよい。また、ヘキサン等の非極性溶媒によって脱脂等の前処理を施してから抽出原料として使用してもよい。脱脂等の前処理を行うことにより、テンニンカの極性溶媒による抽出処理を効率よく行うことができる。 For example, after drying the above plant, it is pulverized as it is or using a crusher, and subjected to extraction with an extraction solvent, thereby inhibiting hyaluronidase inhibitory action, hexosaminidase release inhibitory action, tyrosinase inhibitory action, elastase inhibitory action, estrogen An extract having an action, a fibroblast proliferation promoting action or a cyclic AMP phosphodiesterase inhibitory action can be obtained. Drying may be performed in the sun or using a commonly used dryer. Moreover, after performing pretreatment, such as degreasing, with a nonpolar solvent such as hexane, it may be used as an extraction raw material. By performing pretreatment such as degreasing, extraction with a polar solvent of tenninka can be performed efficiently.
抽出溶媒としては、極性溶媒を用いるのが好ましく、例えば、水、親水性有機溶媒等が挙げられ、これらを単独で又は２種以上を組み合わせて、室温又は溶媒の沸点以下の温度で使用することが好ましい。 As the extraction solvent, it is preferable to use a polar solvent, and examples thereof include water and hydrophilic organic solvents. These may be used alone or in combination of two or more at room temperature or a temperature below the boiling point of the solvent. Is preferred.
抽出溶媒として使用し得る水としては、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等のほか、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、濾過、イオン交換、浸透圧調整、緩衝化等が含まれる。したがって、本発明において抽出溶媒として使用し得る水には、精製水、熱水、イオン交換水、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等も含まれる。 Examples of water that can be used as the extraction solvent include pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, and those subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, and the like. Therefore, the water that can be used as the extraction solvent in the present invention includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.
抽出溶媒として使用し得る親水性有機溶媒としては、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール等の炭素数１〜５の低級脂肪族アルコール；アセトン、メチルエチルケトン等の低級脂肪族ケトン；１，３−ブチレングリコール、プロピレングリコール、グリセリン等の炭素数２〜５の多価アルコール等が挙げられる。 Examples of hydrophilic organic solvents that can be used as extraction solvents include lower aliphatic alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; 1,3-butylene. Examples thereof include polyhydric alcohols having 2 to 5 carbon atoms such as glycol, propylene glycol and glycerin.
２種以上の極性溶媒の混合液を抽出溶媒として使用する場合、その混合比は適宜調整することができる。例えば、水と低級脂肪族アルコールとの混合液を使用する場合には、水１０質量部に対して低級脂肪族アルコール１〜９０質量部を混合することが好ましく、水と低級脂肪族ケトンとの混合液を使用する場合には、水１０質量部に対して低級脂肪族ケトン１〜４０質量部を混合することが好ましく、水と多価アルコールとの混合液を使用する場合には、水１０質量部に対して多価アルコール１０〜９０質量部を混合することが好ましい。 When using the liquid mixture of 2 or more types of polar solvents as an extraction solvent, the mixing ratio can be adjusted suitably. For example, when using a liquid mixture of water and a lower aliphatic alcohol, it is preferable to mix 1 to 90 parts by weight of a lower aliphatic alcohol with respect to 10 parts by weight of water. When using a mixed solution, it is preferable to mix 1 to 40 parts by mass of a lower aliphatic ketone with 10 parts by mass of water, and when using a mixed solution of water and a polyhydric alcohol, water 10 It is preferable to mix 10 to 90 parts by mass of polyhydric alcohol with respect to parts by mass.
抽出処理は、抽出原料に含まれる可溶性成分を抽出溶媒に溶出させ得る限り特に限定はされず、常法に従って行うことができる。例えば、抽出原料の５〜１５倍量（質量比）の抽出溶媒に、抽出原料を浸漬し、常温又は還流加熱下で可溶性成分を抽出させた後、濾過して抽出残渣を除去することにより抽出液を得ることができる。得られた抽出液は、該抽出液の希釈液若しくは濃縮液、該抽出液の乾燥物、又はこれらの粗精製物若しくは精製物を得るために、常法に従って希釈、濃縮、乾燥、精製等の処理を施してもよい。 The extraction treatment is not particularly limited as long as the soluble component contained in the extraction raw material can be eluted in the extraction solvent, and can be performed according to a conventional method. For example, the extraction raw material is immersed in an extraction solvent 5 to 15 times (mass ratio) of the extraction raw material, the soluble components are extracted at room temperature or under reflux, and then filtered to remove the extraction residue. A liquid can be obtained. The obtained extract is diluted, concentrated, dried, purified, etc. according to a conventional method in order to obtain a diluted or concentrated solution of the extract, a dried product of the extract, or a crude purified product or a purified product thereof. Processing may be performed.
精製は、例えば、活性炭処理、吸着樹脂処理、イオン交換樹脂処理等により行うことができる。得られた抽出液はそのままでも抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤又はサイクリックＡＭＰホスホジエステラーゼ阻害剤の有効成分として使用することができるが、濃縮液又は乾燥物としたものの方が使用しやすい。 Purification can be performed by, for example, activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, or the like. The obtained extract can be used as an active ingredient of an anti-inflammatory agent, a whitening agent, a tyrosinase inhibitor, an anti-aging agent, a slimming agent or a cyclic AMP phosphodiesterase inhibitor as it is, but it is a concentrated solution or a dried product. Things are easier to use.
テンニンカからの抽出物は特有の匂いを有しているため、その生理活性の低下を招かない範囲で脱色、脱臭等を目的とする精製を行うことも可能であるが、皮膚化粧料又は美容用飲食品に配合する場合には大量に使用するものではないから、未精製のままでも実用上支障はない。 Since the extract from Tenninka has a unique odor, it can be purified for the purpose of decolorization, deodorization, etc. within the range that does not cause a decrease in its physiological activity. Since it is not used in large quantities when blended in food and drink, there is no practical problem even if it is not purified.
以上のようにして得られるテンニンカからの抽出物は、抗炎症作用、美白作用、チロシナーゼ阻害作用、抗老化作用、スリミング作用又はサイクリックＡＭＰホスホジエステラーゼ阻害作用を有しているため、それぞれの作用を利用して抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤又はサイクリックＡＭＰホスホジエステラーゼ阻害剤の有効成分として用いることができる。 The extract from tenninka obtained as described above has an anti-inflammatory action, a whitening action, a tyrosinase inhibitory action, an anti-aging action, a slimming action, or a cyclic AMP phosphodiesterase inhibitory action. Thus, it can be used as an active ingredient of an anti-inflammatory agent, whitening agent, tyrosinase inhibitor, anti-aging agent, slimming agent or cyclic AMP phosphodiesterase inhibitor.
ここで、テンニンカからの抽出物が有する抗炎症作用は、例えば、ヒアルロニダーゼ阻害作用及び／又はヘキソサミニダーゼ遊離抑制作用に基づいて発揮される。ただし、テンニンカからの抽出物が有する抗炎症作用は、上記作用に基づいて発揮される抗炎症作用に限定されるものではない。なお、テンニンカからの抽出物は、ヒアルロニダーゼ阻害作用又はヘキソサミニダーゼ遊離抑制作用を有するため、それらの作用を利用して、ヒアルロニダーゼ阻害剤又はヘキソサミニダーゼ遊離抑制剤の有効成分として利用することができる。 Here, the anti-inflammatory action of the extract from Tenninka is exhibited based on, for example, a hyaluronidase inhibitory action and / or a hexosaminidase release inhibitory action. However, the anti-inflammatory action which the extract from Tenninka has is not limited to the anti-inflammatory action exhibited based on the above action. In addition, since the extract from Tenninka has a hyaluronidase inhibitory action or a hexosaminidase release inhibitory action, it should be used as an active ingredient of a hyaluronidase inhibitor or a hexosaminidase release inhibitor. Can do.
また、テンニンカからの抽出物が有する美白作用は、例えば、チロシナーゼ阻害作用に基づいて発揮される。ただし、テンニンカからの抽出物が有する美白作用は、上記作用に基づいて発揮される美白作用に限定されるものではない。 Moreover, the whitening action which the extract from Tenninka has is exhibited based on the tyrosinase inhibitory action, for example. However, the whitening action of the extract from tenninka is not limited to the whitening action exhibited based on the above action.
さらに、テンニンカからの抽出物が有する抗老化作用は、例えば、エラスターゼ阻害作用、エストロゲン様作用及び線維芽細胞増殖促進作用からなる群より選ばれる１種又は２種以上の作用に基づいて発揮される。ただし、テンニンカからの抽出物が有する抗老化作用は、上記作用に基づいて発揮される抗老化作用に限定されるものではない。なお、テンニンカからの抽出物は、エラスターゼ阻害作用、エストロゲン様作用又は線維芽細胞増殖促進作用を有するため、それらの作用を利用して、エラスターゼ阻害剤、エストロゲン様作用剤又は線維芽細胞増殖促進剤の有効成分として利用することができる。 Furthermore, the anti-aging effect of the extract from Tenninka is exhibited based on, for example, one or more actions selected from the group consisting of an elastase inhibitory action, an estrogen-like action, and a fibroblast proliferation promoting action. . However, the anti-aging action of the extract from Tenninka is not limited to the anti-aging action exhibited based on the above action. In addition, since the extract from Tenninka has an elastase inhibitory action, an estrogen-like action, or a fibroblast proliferation promoting action, the elastase inhibitor, an estrogen-like action agent, or a fibroblast proliferation promoting agent is utilized using those actions. It can be used as an active ingredient.
さらにまた、テンニンカからの抽出物が有するスリミング作用は、例えば、サイクリックＡＭＰホスホジエステラーゼ阻害作用に基づいて発揮される。ただし、テンニンカからの抽出物が有するスリミング作用は、上記作用に基づいて発揮されるスリミング作用に限定されるものではない。 Furthermore, the slimming action of the extract from Tenninka is exhibited based on, for example, a cyclic AMP phosphodiesterase inhibitory action. However, the slimming action of the extract from tenninka is not limited to the slimming action exhibited based on the above action.
本発明の抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤又はサイクリックＡＭＰホスホジエステラーゼ阻害剤は、テンニンカからの抽出物のみからなるものであってもよいし、上記抽出物を製剤化したものであってもよい。 The anti-inflammatory agent, whitening agent, tyrosinase inhibitor, anti-aging agent, slimming agent or cyclic AMP phosphodiesterase inhibitor of the present invention may consist of only an extract from Tenninka, It may be converted into one.
テンニンカからの抽出物は、デキストリン、シクロデキストリン等の薬学的に許容し得るキャリアーその他任意の助剤を用いて、常法に従い、粉末状、顆粒状、錠剤状、液状等の任意の剤形に製剤化することができる。この際、助剤としては、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、安定剤、矯味・矯臭剤等を用いることができる。テンニンカからの抽出物は、他の組成物（例えば、後述する皮膚化粧料、美容用飲食品等）に配合して使用することができるほか、軟膏剤、外用液剤、貼付剤等として使用することができる。 Extract from Tenninka is prepared into any dosage form such as powder, granule, tablet, liquid, etc. according to conventional methods using pharmaceutically acceptable carriers such as dextrin and cyclodextrin. It can be formulated. In this case, as an auxiliary agent, for example, an excipient, a binder, a disintegrant, a lubricant, a stabilizer, a flavoring / flavoring agent, and the like can be used. Extracts from Tenninka can be used by blending with other compositions (for example, skin cosmetics and cosmetic foods and beverages described later), and also used as ointments, external liquids, patches, etc. Can do.
なお、本発明の抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤又はサイクリックＡＭＰホスホジエステラーゼ阻害剤は、必要に応じて、抗炎症作用、ヒアルロニダーゼ阻害作用、ヘキソサミニダーゼ遊離抑制作用、美白作用、チロシナーゼ阻害作用、抗老化作用、エラスターゼ阻害作用、エストロゲン様作用、線維芽細胞増殖促進作用、スリミング作用又はサイクリックＡＭＰホスホジエステラーゼ阻害作用を有する他の天然抽出物を配合して有効成分として用いることができる。 In addition, the anti-inflammatory agent, whitening agent, tyrosinase inhibitor, anti-aging agent, slimming agent or cyclic AMP phosphodiesterase inhibitor of the present invention may have an anti-inflammatory action, a hyaluronidase inhibitory action, or a hexosaminidase release inhibitor as necessary. Active ingredient with other natural extracts having action, whitening action, tyrosinase inhibitory action, anti-aging action, elastase inhibitory action, estrogen-like action, fibroblast proliferation promoting action, slimming action or cyclic AMP phosphodiesterase inhibitory action Can be used as
本発明の抗炎症剤は、テンニンカからの抽出物が有するヒアルロニダーゼ阻害作用及び／又はヘキソサミニダーゼ遊離抑制作用を通じて、接触性皮膚炎（かぶれ）、乾癬、尋常性天疱瘡等の各種炎症性疾患を予防、治療又は改善することができる。ただし、本発明の抗炎症剤は、これらの用途以外にもヒアルロニダーゼ阻害作用及び／又はヘキソサミニダーゼ遊離抑制作用を発揮することに意義のあるすべての用途に用いることができる。 The anti-inflammatory agent of the present invention has various inflammatory diseases such as contact dermatitis (rash), psoriasis and pemphigus vulgaris through hyaluronidase inhibitory action and / or hexosaminidase release inhibitory action of the extract from Tenninka. Can be prevented, treated or ameliorated. However, the anti-inflammatory agent of the present invention can be used for all purposes other than these uses, which are meaningful for exerting a hyaluronidase inhibitory action and / or a hexosaminidase release inhibitory action.
本発明の美白剤は、テンニンカからの抽出物が有するチロシナーゼ阻害作用を通じて、皮膚色素沈着症、シミ、ソバカス等を予防、治療又は改善することができる。ただし、本発明の美白剤は、これらの用途以外にもチロシナーゼ阻害作用を発揮することに意義のあるすべての用途に用いることができる。 The whitening agent of the present invention can prevent, treat or ameliorate skin pigmentation, blemishes, buckwheat etc. through the tyrosinase inhibitory action of the extract from Tenninka. However, the whitening agent of the present invention can be used for all purposes other than these uses, which are meaningful for exerting a tyrosinase inhibitory action.
本発明のチロシナーゼ阻害剤は、テンニンカからの抽出物が有するチロシナーゼ阻害作用を通じて、皮膚色素沈着症、シミ、ソバカス等を予防、治療又は改善することができる。ただし、本発明のチロシナーゼ阻害剤は、これらの用途以外にもチロシナーゼ阻害作用を発揮することに意義のあるすべての用途に用いることができる。 The tyrosinase inhibitor of the present invention can prevent, treat or ameliorate skin pigmentation, stains, buckwheat etc. through the tyrosinase inhibitory action of the extract from Tenninka. However, the tyrosinase inhibitor of the present invention can be used for all purposes that are meaningful for exerting a tyrosinase inhibitory action in addition to these uses.
本発明の抗老化剤は、テンニンカからの抽出物が有するエラスターゼ阻害作用、エストロゲン様作用及び線維芽細胞増殖促進作用からなる群より選ばれる１種又は２種以上の作用を通じて、皮膚のシワ形成、弾力性低下等の老化現象を予防、治療又は改善することができる。ただし、本発明の抗老化剤は、これらの用途以外にもエラスターゼ阻害作用、エストロゲン様作用及び線維芽細胞増殖促進作用からなる群より選ばれる１種又は２種以上の作用を発揮することに意義のあるすべての用途に用いることができる。 The anti-aging agent of the present invention is a skin wrinkle formation through one or more actions selected from the group consisting of an elastase inhibitory action, an estrogen-like action and a fibroblast proliferation promoting action possessed by an extract from Tenninka. It is possible to prevent, treat or improve an aging phenomenon such as a decrease in elasticity. However, the anti-aging agent of the present invention is significant in that it exhibits one or more actions selected from the group consisting of an elastase inhibitory action, an estrogen-like action and a fibroblast proliferation promoting action in addition to these uses. Can be used for all applications.
本発明のスリミング剤は、テンニンカからの抽出物が有するサイクリックＡＭＰホスホジエステラーゼ阻害作用を通じて、肥満を予防、治療又は改善することができる。ただし、本発明のスリミング剤は、これらの用途以外にもサイクリックＡＭＰホスホジエステラーゼ阻害作用を発揮することに意義のあるすべての用途に用いることができる。 The slimming agent of the present invention can prevent, treat or ameliorate obesity through the cyclic AMP phosphodiesterase inhibitory action of the extract from Tenninka. However, the slimming agent of this invention can be used for all the uses meaningful in exhibiting a cyclic AMP phosphodiesterase inhibitory effect besides these uses.
本発明のサイクリックＡＭＰホスホジエステラーゼ阻害剤は、テンニンカからの抽出物が有するサイクリックＡＭＰホスホジエステラーゼ阻害作用を通じて、肥満を予防、治療又は改善することができる。ただし、本発明のサイクリックＡＭＰホスホジエステラーゼ阻害剤は、これらの用途以外にもサイクリックＡＭＰホスホジエステラーゼ阻害作用を発揮することに意義のあるすべての用途に用いることができる。 The cyclic AMP phosphodiesterase inhibitor of the present invention can prevent, treat or ameliorate obesity through the cyclic AMP phosphodiesterase inhibitory action of the extract from Tenninka. However, the cyclic AMP phosphodiesterase inhibitor of the present invention can be used for all purposes other than these uses that are meaningful for exerting a cyclic AMP phosphodiesterase inhibitory action.
〔皮膚化粧料〕
テンニンカからの抽出物は、ヒアルロニダーゼ阻害作用、ヘキソサミニダーゼ遊離抑制作用、チロシナーゼ阻害作用、エラスターゼ阻害作用、エストロゲン様作用、線維芽細胞増殖促進作用又はサイクリックＡＭＰホスホジエステラーゼ阻害作用を有しており、皮膚に適用した場合の使用感と安全性とに優れているため、皮膚化粧料に配合するのに好適である。この場合、皮膚化粧料には、テンニンカからの抽出物を配合してもよいし、テンニンカからの抽出物から製剤化した抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤又はサイクリックＡＭＰホスホジエステラーゼ阻害剤を配合してもよい。テンニンカからの抽出物、上記抗炎症剤、上記美白剤、上記チロシナーゼ阻害剤、上記抗老化剤、上記スリミング剤又は上記サイクリックＡＭＰホスホジエステラーゼ阻害剤を皮膚化粧料に配合することによって、皮膚化粧料にヒアルロニダーゼ阻害作用、ヘキソサミニダーゼ遊離抑制作用、チロシナーゼ阻害作用、エラスターゼ阻害作用、エストロゲン様作用、線維芽細胞増殖促進作用又はサイクリックＡＭＰホスホジエステラーゼ阻害作用を付与することができる。
[Skin cosmetic]
Extract from Tenninka has hyaluronidase inhibitory action, hexosaminidase release inhibitory action, tyrosinase inhibitory action, elastase inhibitory action, estrogen-like action, fibroblast proliferation promoting action or cyclic AMP phosphodiesterase inhibitory action, Since it is excellent in usability and safety when applied to the skin, it is suitable for blending into skin cosmetics. In this case, the skin cosmetic may contain an extract from tenninka, or an anti-inflammatory agent, whitening agent, tyrosinase inhibitor, anti-aging agent, slimming agent, or cypress formulated from an extract from tenninka. A click AMP phosphodiesterase inhibitor may be added. By blending an extract from Tenninka, the anti-inflammatory agent, the whitening agent, the tyrosinase inhibitor, the anti-aging agent, the slimming agent or the cyclic AMP phosphodiesterase inhibitor into the skin cosmetic, Hyaluronidase inhibitory action, hexosaminidase release inhibitory action, tyrosinase inhibitory action, elastase inhibitory action, estrogen-like action, fibroblast proliferation promoting action or cyclic AMP phosphodiesterase inhibitory action can be imparted.
テンニンカからの抽出物を配合し得る皮膚化粧料の種類は、特に限定されるものではなく、例えば、軟膏、クリーム、乳液、ローション、パック、ゼリー、ファンデーション、リップクリーム、口紅、入浴剤等が挙げられる。 The types of skin cosmetics that can be blended with the extract from Tenninka are not particularly limited, and examples thereof include ointments, creams, emulsions, lotions, packs, jellies, foundations, lip balms, lipsticks, bathing agents, and the like. It is done.
テンニンカからの抽出物を皮膚化粧料に配合する場合、その配合量は、皮膚化粧料の種類に応じて適宜調整することができるが、好適な配合率は、標準的な抽出物に換算して約０．０００１〜１０質量％であり、特に好適な配合率は、標準的な抽出物に換算して約０．００１〜１質量％である。 When the extract from Tenninka is blended into the skin cosmetic, the blending amount can be adjusted as appropriate according to the type of skin cosmetic, but the preferred blending rate is converted to a standard extract. About 0.0001 to 10% by mass, and a particularly suitable blending ratio is about 0.001 to 1% by mass in terms of a standard extract.
本発明の皮膚化粧料は、テンニンカからの抽出物が有するヒアルロニダーゼ阻害作用、ヘキソサミニダーゼ遊離抑制作用、チロシナーゼ阻害作用、エラスターゼ阻害作用、エストロゲン様作用、線維芽細胞増殖促進作用又はサイクリックＡＭＰホスホジエステラーゼ阻害作用を妨げない限り、通常の皮膚化粧料の製造に用いられる主剤、助剤又はその他の成分、例えば、収斂剤、殺菌・抗菌剤、美白剤、紫外線吸収剤、保湿剤、細胞賦活剤、消炎・抗アレルギー剤、抗酸化・活性酸素除去剤、油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、香料等を併用することができる。このように併用することで、より一般性のある製品となり、また、併用された上記成分との間の相乗作用が通常期待される以上の優れた効果をもたらすことがある。 The skin cosmetic composition of the present invention comprises a hyaluronidase inhibitory action, hexosaminidase release inhibitory action, tyrosinase inhibitory action, elastase inhibitory action, estrogen-like action, fibroblast proliferation promoting action or cyclic AMP phosphodiesterase possessed by an extract from Tenninka As long as the inhibitory action is not hindered, main agents, auxiliaries or other components used in the production of ordinary skin cosmetics, such as astringents, bactericides / antibacterial agents, whitening agents, UV absorbers, humectants, cell activators, Anti-inflammatory / antiallergic agents, antioxidant / active oxygen scavengers, fats and oils, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, fragrances and the like can be used in combination. By using in this way, it becomes a more general product, and a synergistic action with the above-mentioned components used in combination may bring about an excellent effect that is usually expected.
〔美容用飲食品〕
テンニンカからの抽出物は、ヒアルロニダーゼ阻害作用、ヘキソサミニダーゼ遊離抑制作用、チロシナーゼ阻害作用、エラスターゼ阻害作用、エストロゲン様作用、線維芽細胞増殖促進作用又はサイクリックＡＭＰホスホジエステラーゼ阻害作用を有しており、消化管で消化されるようなものではないことが確認されており、安全性にも優れているため、美容用飲食品に配合するのに好適である。この場合に、テンニンカからの抽出物をそのまま配合してもよいし、テンニンカからの抽出物から製剤化した抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤又はサイクリックＡＭＰホスホジエステラーゼ阻害剤を配合してもよい。
[Beauty food and drink]
Extract from Tenninka has hyaluronidase inhibitory action, hexosaminidase release inhibitory action, tyrosinase inhibitory action, elastase inhibitory action, estrogen-like action, fibroblast proliferation promoting action or cyclic AMP phosphodiesterase inhibitory action, It has been confirmed that it is not digested in the digestive tract, and is excellent in safety, so it is suitable for blending into cosmetic foods and drinks. In this case, an extract from Tenninka may be added as it is, or an anti-inflammatory agent, whitening agent, tyrosinase inhibitor, anti-aging agent, slimming agent, or cyclic AMP phosphodiesterase inhibition formulated from an extract from Tenninka An agent may be blended.
ここで、「美容用飲食品」とは、美肌を図ることを目的とした飲食物、又は肌荒れ、皮膚の老化及びこれらに伴って生じる各種皮膚疾患を予防・改善することを目的とした飲食物を意味する。 Here, “beauty food and drink” refers to food and drink intended for beautifying the skin, or food and drink intended to prevent and improve rough skin, aging of the skin and various skin diseases associated therewith. Means.
上記テンニンカからの抽出物、又はそれから製剤化した抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤若しくはサイクリックＡＭＰホスホジエステラーゼ阻害剤を美容用飲食品に配合する場合、それらにおける有効成分の配合量は、使用目的、症状、性別等を考慮して適宜変更することができるが、添加対象飲食品の一般的な摂取量を考慮して、成人１日あたりの抽出物摂取量が約１〜１０００ｍｇになるようにするのが好ましい。 When an extract from the above tenninka or an anti-inflammatory agent, whitening agent, tyrosinase inhibitor, anti-aging agent, slimming agent, or cyclic AMP phosphodiesterase inhibitor formulated therefrom is incorporated into a cosmetic food or drink, the active ingredient in them The amount of extract can be appropriately changed in consideration of the purpose of use, symptoms, gender, etc., but the amount of extract per day for adults is approximately It is preferable to be 1 to 1000 mg.
本発明の美容用飲食品は、テンニンカからの抽出物をその活性を妨げないような任意の飲食品に配合したものであってもよいし、テンニンカからの抽出物を主成分とする栄養補助食品であってもよい。 The cosmetic food and drink of the present invention may be an extract from tenninka blended with any food or drink that does not impede its activity, or a dietary supplement mainly composed of an extract from tenninka It may be.
本発明の美容用飲食品を製造する際には、例えば、デキストリン、デンプン等の糖類；ゼラチン、大豆タンパク、トウモロコシタンパク等のタンパク質；アラニン、グルタミン、イソロイシン等のアミノ酸類；セルロース、アラビアゴム等の多糖類；大豆油、中鎖脂肪酸トリグリセリド等の油脂類等の任意の助剤を添加して任意の形状の飲食品にすることができる。 When producing the cosmetic food and drink of the present invention, for example, sugars such as dextrin and starch; proteins such as gelatin, soybean protein and corn protein; amino acids such as alanine, glutamine and isoleucine; cellulose and gum arabic Polysaccharides: Foods and drinks of any shape can be obtained by adding any auxiliary agent such as oils and fats such as soybean oil and medium chain fatty acid triglycerides.
テンニンカからの抽出物を配合し得る美容用飲食品は特に限定されないが、その具体例としては、清涼飲料、炭酸飲料、栄養飲料、果実飲料、乳酸飲料等の飲料（これらの飲料の濃縮原液及び調整用粉末を含む）；アイスクリーム、アイスシャーベット、かき氷等の冷菓；そば、うどん、はるさめ、ぎょうざの皮、しゅうまいの皮、中華麺、即席麺等の麺類；飴、チューインガム、キャンディー、ガム、チョコレート、錠菓、スナック菓子、ビスケット、ゼリー、ジャム、クリーム、焼き菓子等の菓子類；かまぼこ、ハム、ソーセージ等の水産・畜産加工食品；加工乳、発酵乳等の乳製品；サラダ油、てんぷら油、マーガリン、マヨネーズ、ショートニング、ホイップクリーム、ドレッシング等の油脂及び油脂加工食品；ソース、たれ等の調味料；スープ、シチュー、サラダ、惣菜、漬物；その他種々の形態の健康・栄養補助食品；錠剤、カプセル剤、ドリンク剤等が挙げられ、これらの飲食品に上記テンニンカからの抽出物を配合するときに、通常用いられる補助的な原料や添加物を併用することができる。 Beauty foods and drinks that can be blended with extracts from Tenninka are not particularly limited, but specific examples thereof include beverages such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, and lactic acid drinks (concentrated concentrates of these drinks and Including ice cream, ice sherbet, shaved ice, etc .; noodles such as buckwheat, udon, harusame, gyoza skin, cucumber skin, Chinese noodles, instant noodles; rice cake, chewing gum, candy, gum, chocolate , Tablet confectionery, snack confectionery, biscuits, jelly, jam, cream, baked confectionery, etc .; fish and shellfish processed foods such as kamaboko, ham, sausage; dairy products such as processed milk, fermented milk; salad oil, tempura oil, margarine , Mayonnaise, shortening, whipped cream, dressing and other fats and oils processed foods; sauces, sauces, etc. Soups, stews, salads, prepared dishes, pickles; other various forms of health and nutritional supplements; tablets, capsules, drinks, etc. In addition, commonly used auxiliary raw materials and additives can be used in combination.
なお、本発明の抗炎症剤、美白剤、チロシナーゼ阻害剤、抗老化剤、スリミング剤、サイクリックＡＭＰホスホジエステラーゼ阻害剤、皮膚化粧料又は美容用飲食品は、ヒトに対して好適に適用されるものであるが、それぞれの作用効果が奏される限り、ヒト以外の動物に対して適用することもできる。 In addition, the anti-inflammatory agent, whitening agent, tyrosinase inhibitor, anti-aging agent, slimming agent, cyclic AMP phosphodiesterase inhibitor, skin cosmetic or cosmetic food or drink of the present invention is suitably applied to humans. However, it can be applied to animals other than humans as long as the respective effects are exhibited.
以下、製造例、試験例及び配合例を示し、本発明を具体的に説明するが、本発明は下記の各例に何ら制限されるものではない。 Hereinafter, although a manufacture example, a test example, and a compounding example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to each following example at all.
〔製造例１〕テンニンカ地上部抽出物の製造
細切りにしたテンニンカの地上部の乾燥物２００ｇに抽出溶媒２０００ｍＬを加え、還流抽出器で８０℃にて２時間加熱抽出し、熱時濾過した。残渣についてさらに同様の抽出処理を行った。得られた各抽出液を合わせて減圧下に濃縮し、乾燥してテンニンカ地上部抽出物を得た。抽出溶媒として、水、５０質量％エタノール（水とエタノールとの質量比＝１：１）、８０質量％エタノール（水とエタノールとの質量比＝１：４）を用いたときの各抽出物の収率を表１に示す。
[Production Example 1] Production of above-ground extract of Tenninka 2000 mL of extraction solvent was added to 200 g of the dried above-ground portion of Tenninka, and the mixture was heated and extracted at 80 ° C for 2 hours with a reflux extractor and filtered while hot. The same extraction process was further performed on the residue. The obtained extracts were combined, concentrated under reduced pressure, and dried to obtain an above-ground extract of a tenninka. As the extraction solvent, water, 50% by mass ethanol (mass ratio of water and ethanol = 1: 1), 80% by mass ethanol (mass ratio of water and ethanol = 1: 4) The yield is shown in Table 1.
［表１］
試 料 抽出溶媒 抽出物収率（％）
１ 水 ６．８
２ ５０％エタノール ９．６
３ ８０％エタノール ７．８
[Table 1]
Sample extraction solvent extract yield (%)
1 water 6.8
2 50% ethanol 9.6
3 80% ethanol 7.8
〔製造例２〕テンニンカ根部抽出物の製造
細切りにしたテンニンカの根部の乾燥物２００ｇに抽出溶媒２０００ｍＬを加え、還流抽出器で８０℃にて２時間加熱抽出し、熱時濾過した。残渣についてさらに同様の抽出処理を行った。得られた各抽出液を合わせて減圧下に濃縮し、乾燥してテンニンカ根部抽出物を得た。抽出溶媒として、水、５０質量％エタノール（水とエタノールとの質量比＝１：１）、８０質量％エタノール（水とエタノールとの質量比＝１：４）を用いたときの各抽出物の収率を表２に示す。
[Production Example 2] Production of Tenninka Root Extract Extract 2000 ml of extraction solvent was added to 200 g of dried garlic root extract, and the mixture was heated and extracted at 80 ° C for 2 hours with a reflux extractor and filtered while hot. The same extraction process was further performed on the residue. The obtained extracts were combined, concentrated under reduced pressure, and dried to obtain a Tenninka root extract. As the extraction solvent, water, 50% by mass ethanol (mass ratio of water and ethanol = 1: 1), 80% by mass ethanol (mass ratio of water and ethanol = 1: 4) The yield is shown in Table 2.
［表２］
試 料 抽出溶媒 抽出物収率（％）
４ 水 ４．３
５ ５０％エタノール ５．７
６ ８０％エタノール ４．７
[Table 2]
Sample extraction solvent extract yield (%)
4 Water 4.3
5 50% ethanol 5.7
6 80% ethanol 4.7
〔製造例３〕テンニンカ果実部抽出物の製造
細切りにしたテンニンカの果実部の乾燥物２００ｇに抽出溶媒２０００ｍＬを加え、還流抽出器で８０℃にて２時間加熱抽出し、熱時濾過した。残渣についてさらに同様の抽出処理を行った。得られた各抽出液を合わせて減圧下に濃縮し、乾燥してテンニンカ果実部抽出物を得た。抽出溶媒として、水、５０質量％エタノール（水とエタノールとの質量比＝１：１）、８０質量％エタノール（水とエタノールとの質量比＝１：４）を用いたときの各抽出物の収率を表３に示す。
[Production Example 3] Production of Tenninka fruit part extract To 200 g of dried fruit of Tenninka fruit part, 2000 mL of extraction solvent was added, and the mixture was heated and extracted at 80 ° C for 2 hours with a reflux extractor and filtered while hot. The same extraction process was further performed on the residue. The obtained extracts were combined, concentrated under reduced pressure, and dried to obtain a Tenninka fruit part extract. As the extraction solvent, water, 50% by mass ethanol (mass ratio of water and ethanol = 1: 1), 80% by mass ethanol (mass ratio of water and ethanol = 1: 4) The yield is shown in Table 3.
［表３］
試 料 抽出溶媒 抽出物収率（％）
７ 水 ４．６
８ ５０％エタノール ５．８
９ ８０％エタノール ４．６
[Table 3]
Sample extraction solvent extract yield (%)
7 Water 4.6
8 50% ethanol 5.8
9 80% ethanol 4.6
〔試験例１〕ヒアルロニダーゼ阻害作用試験
製造例１により得られたテンニンカ地上部抽出物（試料１〜３）、製造例２により得られたテンニンカ根部抽出物（試料４〜６）及び製造例３により得られたテンニンカ果実部抽出物（試料７〜９）について、以下のようにしてヒアルロニダーゼ阻害作用を試験した。
[Test Example 1] Hyaluronidase Inhibitory Action Test According to Tenninka ground extract (Samples 1 to 3) obtained in Production Example 1, Tenninka root extract (Samples 4 to 6) obtained in Production Example 2 and Production Example 3 About the obtained Tenninka fruit part extract (samples 7-9), the hyaluronidase inhibitory effect was tested as follows.
０．１ｍｏｌ／Ｌの酢酸緩衝液（ｐＨ３．５）に各試料（試料１〜９）を溶解させた試料溶液０．２ｍＬとヒアルロニダーゼ溶液（Type IV-S(from bovine testis)，SIGMA社製，４００ユニット／ｍＬ）０．１ｍＬとを混合し、３７℃で２０分間反応させた。さらに、活性化剤として２．５ｍｍｏｌ／Ｌの塩化カルシウム０．２ｍＬを加え、３７℃で２０分間反応させ、酵素を活性化させた。その後、０．４ｍｇ／ｍＬのヒアルロン酸カリウム溶液（from rooster comb）０．５ｍＬを加え、３７℃で４０分間反応させ、０．４ｍｏｌ／Ｌの水酸化ナトリウム溶液０．２ｍＬを加えるとともに氷冷し反応を停止させた。 0.2 mL of a sample solution prepared by dissolving each sample (samples 1 to 9) in 0.1 mol / L acetate buffer (pH 3.5) and a hyaluronidase solution (Type IV-S (from bovine testis), manufactured by SIGMA) 400 units / mL) and 0.1 mL were mixed and reacted at 37 ° C. for 20 minutes. Further, 0.2 mL of 2.5 mmol / L calcium chloride was added as an activator and reacted at 37 ° C. for 20 minutes to activate the enzyme. Thereafter, 0.5 mL of 0.4 mg / mL potassium hyaluronate solution (from rooster comb) was added and reacted at 37 ° C. for 40 minutes, and 0.2 mL of 0.4 mol / L sodium hydroxide solution was added and cooled with ice. The reaction was stopped.
各反応溶液にホウ酸溶液０．２ｍＬを加え、沸騰湯浴中で３分間加熱した後、１０分間氷冷した。次いで、ｐ−ＤＡＢＡ試薬（ｐ−ジメチルアミノベンズアルデヒド１０ｇを１０Ｎの塩酸１２．５ｍＬと酢酸８７．５ｍＬの混合液に溶解し、酢酸で１０倍に希釈したもの）６ｍＬを加え、３７℃で２０分間反応させた。その後、波長５８５ｎｍにおける吸光度を測定した。同様の方法で空試験を行い補正した。得られた結果から、下記の式より、ヒアルロニダーゼ阻害率（％）を算出した。 0.2 mL of boric acid solution was added to each reaction solution, heated in a boiling water bath for 3 minutes, and then ice-cooled for 10 minutes. Next, 6 mL of p-DABA reagent (10 g of p-dimethylaminobenzaldehyde dissolved in 12.5 mL of 10N hydrochloric acid and 87.5 mL of acetic acid and diluted 10-fold with acetic acid) was added, and the mixture was added at 37 ° C. for 20 minutes. Reacted. Thereafter, the absorbance at a wavelength of 585 nm was measured. A blank test was performed and corrected in the same manner. From the obtained results, the hyaluronidase inhibition rate (%) was calculated from the following formula.
ヒアルロニダーゼ阻害率(％)＝{１−(Ｓｔ−Ｓｂ)／(Ｃｔ−Ｃｂ)}×１００
式中、Ｓｔは試料溶液の波長５８５ｎｍにおける吸光度を表し、Ｓｂは試料溶液ブランクの波長５８５ｎｍにおける吸光度を表し、Ｃｔはコントロール溶液の波長５８５ｎｍにおける吸光を表し、Ｃｂはコントロール溶液ブランクの波長５８５ｎｍにおける吸光度を表す。
Hyaluronidase inhibition rate (%) = {1− (St−Sb) / (Ct−Cb)} × 100
In the formula, St represents the absorbance of the sample solution at a wavelength of 585 nm, Sb represents the absorbance of the sample solution blank at a wavelength of 585 nm, Ct represents the absorbance of the control solution at a wavelength of 585 nm, and Cb represents the absorbance of the control solution blank at a wavelength of 585 nm. Represents.
試料濃度を段階的に減少させて上記ヒアルロニダーゼ阻害率（％）の測定を行い、ヒアルロニダーゼ活性を５０％阻害する試料濃度ＩＣ５０（μｇ／ｍＬ；ｐｐｍ）を内挿法により求めた。
上記試験の結果を表４に示す。
The sample concentration was decreased stepwise to measure the hyaluronidase inhibition rate (%), and the sample concentration IC 50 (μg / mL; ppm) that inhibited the hyaluronidase activity by 50% was determined by interpolation.
Table 4 shows the results of the above test.
［表４］
試 料 ＩＣ ５０ （μｇ／ｍＬ）
１ ＞４００
２ ２６９．１
３ ＞４００
４ ２４８．３
５ ２２４．５
６ ２６８．１
７ ＞４００
８ ３８３．５
９ ＞４００
[Table 4]
Sample IC 50 (μg / mL)
1> 400
2 269.1
3> 400
4 248.3
5 224.5
6 268.1
7> 400
8 383.5
9> 400
表４に示すように、テンニンカの地上部、根部及び果実部からの抽出物は、優れたヒアルロニダーゼ阻害作用を有することが確認された。また、ヒアルロニダーゼ阻害作用の程度は、抽出物の濃度によって調節できることが確認された。 As shown in Table 4, it was confirmed that the extracts from the above-ground part, root part, and fruit part of Tenninka have an excellent hyaluronidase inhibitory action. It was also confirmed that the degree of hyaluronidase inhibitory action can be adjusted by the concentration of the extract.
〔試験例２〕ヘキソサミニダーゼ遊離抑制作用試験
製造例１で得られたテンニンカ地上部抽出物（試料１〜３）、製造例２で得られたテンニンカ根部抽出物（試料４〜６）及び製造例３で得られたテンニンカ果実部抽出物（試料７〜９）について、以下のようにしてヘキソサミニダーゼ遊離抑制作用を試験した。
[Test Example 2] Hexosaminidase release inhibitory action test Tenninka ground extract (Samples 1 to 3) obtained in Production Example 1, Tenninka root extract (Samples 4 to 6) obtained in Production Example 2 and About the Tenninka fruit part extract (samples 7-9) obtained by manufacture example 3, the hexosaminidase release inhibitory effect was tested as follows.
ラット好塩基球白血病細胞（ＲＢＬ−２Ｈ３）を１５％ＦＢＳ含有Ｓ−ＭＥＭ培地を用いて培養した後、トリプシン処理により細胞を回収した。回収した細胞を４．０×１０５ｃｅｌｌｓ／ｍＬの細胞密度になるように希釈し、DNP-specific IgEの終濃度が０．５μｇ／ｍＬとなるようにDNP-specific IgEを添加した後、９６ウェルプレートに１ウェルあたり１００μＬずつ播種し、一晩培養した。培養終了後、培地を抜き、シラガニアン緩衝液５００μＬにて洗浄を２回行った。 Rat basophil leukemia cells (RBL-2H3) were cultured in S-MEM medium containing 15% FBS, and then cells were collected by trypsin treatment. The collected cells are diluted to a cell density of 4.0 × 10 5 cells / mL, and after adding DNP-specific IgE so that the final concentration of DNP-specific IgE is 0.5 μg / mL, 96 100 μL per well was seeded on a well plate and cultured overnight. After completion of the culture, the medium was removed and washing was performed twice with 500 μL of Silaganian buffer.
次に、シラガニアン緩衝液３０μＬ及び同緩衝液に溶解した試料溶液１０μＬを加え、３７℃で１０分間静置した。その後、１００ｎｇ／ｍＬのＤＮＰ−ＢＳＡ溶液１０μＬを加え、３７℃で１５分間静置し、ヘキソサミニダーゼを遊離させた。その後、９６ウェルプレートを氷上に静置することによりヘキソサミニダーゼの遊離を停止させた。各ウェルの細胞上清１０μＬ及び１ｍｍｏｌ／Ｌのｐ−ニトロフェニル−Ｎ−アセチル−α−Ｄ−グルコサミニド（ｐ−ＮＡＧ）溶液１０μＬを、新たな９６ウェルプレートに添加し、３７℃で１時間反応させた。反応終了後、各ウェルに０．１ｍｏｌ／ＬのＮａ２ＣＯ３／ＮａＨＣＯ３２５０μＬを加え、波長４１５ｎｍにおける吸光度を測定した。同様にして試料を添加せずに、細胞上清１０μＬと０．１ｍｏｌ／ＬのＮａ２ＣＯ３／ＮａＨＣＯ３２５０μＬとの混合液の吸光度を測定した。また、同様にして試料を添加しｐ−ＮＡＧを添加せずに吸光度を測定した。得られた結果から、下記の式によりヘキソサミニダーゼ遊離抑制率（％）を算出した。 Next, 30 μL of the Siraganian buffer and 10 μL of the sample solution dissolved in the same buffer were added, and the mixture was allowed to stand at 37 ° C. for 10 minutes. Thereafter, 10 μL of a 100 ng / mL DNP-BSA solution was added, and the mixture was allowed to stand at 37 ° C. for 15 minutes to release hexosaminidase. Thereafter, the release of hexosaminidase was stopped by allowing the 96-well plate to stand on ice. 10 μL of cell supernatant in each well and 10 μL of 1 mmol / L p-nitrophenyl-N-acetyl-α-D-glucosaminide (p-NAG) solution were added to a new 96-well plate and reacted at 37 ° C. for 1 hour. I let you. After completion of the reaction, 250 μL of 0.1 mol / L Na 2 CO 3 / NaHCO 3 was added to each well, and the absorbance at a wavelength of 415 nm was measured. Similarly, the absorbance of a mixed solution of 10 μL of cell supernatant and 250 μL of 0.1 mol / L Na 2 CO 3 / NaHCO 3 was measured without adding a sample. Similarly, the sample was added and the absorbance was measured without adding p-NAG. From the obtained results, the hexosaminidase release inhibition rate (%) was calculated by the following formula.
ヘキソサミニダーゼ遊離抑制率(％)＝{１−(Ｂ−Ｃ)／Ａ}×１００
式中、Ａは試料無添加時の吸光度を表し、Ｂは試料添加時の吸光度を表し、Ｃは試料添加・ｐ−ＮＡＧ無添加時の吸光度を表す。
Inhibition rate of hexosaminidase release (%) = {1− (B−C) / A} × 100
In the formula, A represents the absorbance when the sample was not added, B represents the absorbance when the sample was added, and C represents the absorbance when the sample was added and p-NAG was not added.
試料溶液の濃度を段階的に減少させて、上記ヘキソサミニダーゼ遊離抑制率（％）を算出し、ヘキソサミニダーゼ遊離抑制率が５０％になる試料濃度ＩＣ５０（μｇ／ｍＬ；ｐｐｍ）を内挿法により算出した。
上記試験の結果を表５に示す。
The concentration of the sample solution is decreased stepwise to calculate the hexosaminidase release inhibition rate (%), and the sample concentration IC 50 (μg / mL; ppm) at which the hexosaminidase release inhibition rate is 50%. Was calculated by interpolation.
The results of the above test are shown in Table 5.
［表５］
試 料 ＩＣ ５０ （μｇ／ｍＬ）
１ ３４８
２ １３６
３ １０５
４ ９５．５
５ ７３．１
６ ８０．０
７ ３３５
８ ７９．７
９ ４３．８
[Table 5]
Sample IC 50 (μg / mL)
1 348
2 136
3 105
4 95.5
5 73.1
6 80.0
7 335
8 79.7
9 43.8
表５に示すように、テンニンカの地上部、根部及び果実部からの抽出物は、優れたヘキソサミニダーゼ遊離抑制作用を有することが確認された。また、ヘキソサミニダーゼ遊離抑制作用の程度は、抽出物の濃度によって調節できることが確認された。 As shown in Table 5, it was confirmed that the extracts from the above-ground part, root part, and fruit part of Tenninka have an excellent hexosaminidase release inhibitory action. Moreover, it was confirmed that the degree of hexosaminidase release inhibitory action can be adjusted by the concentration of the extract.
〔試験例３〕チロシナーゼ阻害作用試験
製造例１で得られたテンニンカ地上部抽出物（試料１〜３）、製造例２で得られたテンニンカ根部抽出物（試料４〜６）及び製造例３で得られたテンニンカ果実部抽出物（試料７〜９）について、以下のようにしてチロシナーゼ阻害作用を試験した。
[Test Example 3] Tyrosinase inhibitory action test Tenninka ground extract (Samples 1 to 3) obtained in Production Example 1, Tenninka root extract (Samples 4 to 6) obtained in Production Example 2 and Production Example 3 About the obtained tenninka fruit part extract (samples 7-9), the tyrosinase inhibitory effect was tested as follows.
４８ウェルプレートに、Mcllvaine緩衝液（ｐＨ６．８）０．２ｍＬ、０．３ｍｇ／ｍＬのチロシン溶液０．０６ｍＬ及び試料の２５％ＤＭＳＯ溶液０．１８ｍＬ（試料１〜６の試料濃度：２００μｇ／ｍＬ，試料７及び８の試料濃度：４００μｇ／ｍＬ，試料９の試料濃度：１００μｇ／ｍＬ）を添加し、３７℃で１０分間静置した。これに、２５００ユニット／ｍＬのチロシナーゼ溶液０．０２ｍＬを加え、引き続き３７℃で１５分間反応させた。反応終了後、波長４７５ｎｍにおける吸光度を測定した。同様の方法で空試験を行い補正した。得られた結果から、下記の式によりチロシナーゼ阻害率（％）を算出した。 In a 48-well plate, 0.2 mL of Mcllvaine buffer (pH 6.8), 0.06 mL of 0.3 mg / mL tyrosine solution and 0.18 mL of 25% DMSO solution of the sample (sample concentration of samples 1 to 6: 200 μg / mL) Sample concentration of Samples 7 and 8: 400 μg / mL, Sample concentration of Sample 9: 100 μg / mL) was added and allowed to stand at 37 ° C. for 10 minutes. To this, 0.02 mL of 2500 unit / mL tyrosinase solution was added, followed by reaction at 37 ° C. for 15 minutes. After completion of the reaction, the absorbance at a wavelength of 475 nm was measured. A blank test was performed and corrected in the same manner. From the obtained results, the tyrosinase inhibition rate (%) was calculated by the following formula.
チロシナーゼ阻害率(％)＝{１−(Ｓｔ−Ｓｂ)／(Ｃｔ−Ｃｂ)}×１００
式中、Ｓｔは試料溶液の波長４７５ｎｍにおける吸光度を表し、Ｓｂは試料溶液ブランクの波長４７５ｎｍにおける吸光度を表し、Ｃｔはコントロール溶液の波長４７５ｎｍにおける吸光度を表し、Ｃｂはコントロール溶液ブランクの波長４７５ｎｍにおける吸光度を表す。
上記試験の結果を表６に示す。
Tyrosinase inhibition rate (%) = {1− (St−Sb) / (Ct−Cb)} × 100
In the formula, St represents the absorbance of the sample solution at a wavelength of 475 nm, Sb represents the absorbance of the sample solution blank at a wavelength of 475 nm, Ct represents the absorbance of the control solution at a wavelength of 475 nm, and Cb represents the absorbance of the control solution blank at a wavelength of 475 nm. Represents.
The results of the above test are shown in Table 6.
［表６］
試 料 チロシナーゼ阻害率（％）
１ １１．２
２ １０．４
３ ９．３
４ ２５．０
５ ３０．７
６ ２６．７
７ １７．６
８ ６．９
９ １．９
[Table 6]
Sample tyrosinase inhibition rate (%)
1 11.2
2 10.4
3 9.3
4 25.0
5 30.7
6 26.7
7 17.6
8 6.9
9 1.9
表６に示すように、テンニンカの地上部、根部及び果実部からの抽出物は、優れたチロシナーゼ阻害作用を有することが確認された。 As shown in Table 6, it was confirmed that the extracts from the above-ground part, root part, and fruit part of Tenninka have an excellent tyrosinase inhibitory action.
〔試験例４〕エラスターゼ阻害作用試験
製造例１で得られたテンニンカ地上部抽出物（試料１〜３）、製造例２で得られたテンニンカ根部抽出物（試料４〜６）及び製造例３で得られたテンニンカ果実部抽出物（試料７〜９）について、以下のようにしてエラスターゼ阻害作用を試験した。
[Test Example 4] Elastase inhibitory action test Tenninka ground extract (Samples 1 to 3) obtained in Production Example 1, Tenninka root extract (Samples 4 to 6) obtained in Production Example 2 and Production Example 3 About the obtained tenninka fruit part extract (samples 7-9), the elastase inhibitory effect was tested as follows.
９６ウェルプレートにて、０．２ｍｏｌ／Ｌのトリス塩酸緩衝液（ｐＨ８．０）で調製した試料溶液５０μＬ及び２０μｇ／ｍＬのエラスターゼ・タイプIII溶液５０μＬを混合した。その後、上記緩衝液で調製した０．４５１４ｍｇ／ｍＬのN-succinyl-Ala-Ala-Ala-p-nitroanilide１００μＬを添加して、２５℃で１５分間反応させた。反応終了後、波長４１５ｎｍにおける吸光度を測定した。同様の方法で空試験を行い補正した。得られた結果から、下記の式によりエラスターゼ阻害率（％）を算出した。 In a 96-well plate, 50 μL of a sample solution prepared with 0.2 mol / L Tris-HCl buffer (pH 8.0) and 50 μL of 20 μg / mL elastase type III solution were mixed. Thereafter, 100 μL of 0.4514 mg / mL N-succinyl-Ala-Ala-Ala-p-nitroanilide prepared in the above buffer solution was added and reacted at 25 ° C. for 15 minutes. After completion of the reaction, absorbance at a wavelength of 415 nm was measured. A blank test was performed and corrected in the same manner. From the obtained results, the elastase inhibition rate (%) was calculated by the following formula.
エラスターゼ阻害率(％)＝{１−(Ｃ−Ｄ)／(Ａ−Ｂ)}×１００
式中、Ａは試料無添加・酵素添加時の波長４１５ｎｍにおける吸光度を表し、Ｂは試料無添加・酵素無添加時の波長４１５ｎｍにおける吸光度を表し、Ｃは試料添加・酵素添加時の波長４１５ｎｍにおける吸光度を表し、Ｄは試料添加・酵素無添加時の波長４１５ｎｍにおける吸光度を表す。
Elastase inhibition rate (%) = {1- (C−D) / (A−B)} × 100
In the formula, A represents the absorbance at a wavelength of 415 nm when no sample was added and the enzyme was added, B represents the absorbance at a wavelength of 415 nm when no sample was added and the enzyme was not added, and C was at a wavelength of 415 nm when the sample was added and the enzyme was not added. Absorbance is represented, and D represents absorbance at a wavelength of 415 nm when a sample is added and no enzyme is added.
試料濃度を段階的に減少させて上記エラスターゼ阻害率（％）の測定を行い、エラスターゼの活性を５０％阻害する試料濃度ＩＣ５０（μｇ／ｍＬ；ｐｐｍ）を内挿法により求めた。
上記試験の結果を表７に示す。
The elastase inhibition rate (%) was measured by gradually reducing the sample concentration, and the sample concentration IC 50 (μg / mL; ppm) that inhibits the elastase activity by 50% was determined by interpolation.
Table 7 shows the results of the above test.
［表７］
試 料 ＩＣ ５０ （μｇ／ｍＬ）
１ ２３０．０
２ ７７．１
３ ７２．８
４ ３９．０
５ ２９．９
６ ２３．５
７ ＞４００
８ ８０．３
９ ２４６
[Table 7]
Sample IC 50 (μg / mL)
1 230.0
2 77.1
3 72.8
4 39.0
5 29.9
6 23.5
7> 400
8 80.3
9 246
表７に示すように、テンニンカの地上部、根部及び果実部からの抽出物は、優れたエラスターゼ阻害作用を有することが確認された。また、エラスターゼ阻害作用の程度は、抽出物の濃度によって調節できることが確認された。 As shown in Table 7, it was confirmed that the extracts from the above-ground part, root part, and fruit part of Tenninka have an excellent elastase inhibitory action. It was also confirmed that the degree of elastase inhibitory action can be adjusted by the concentration of the extract.
〔試験例５〕エストロゲン様作用試験
製造例１で得られたテンニンカ地上部抽出物（試料１〜３）、製造例２で得られたテンニンカ根部抽出物（試料４〜６）及び製造例３で得られたテンニンカ果実部抽出物（試料７〜９）について、以下のようにしてエストロゲン様作用を試験した。
[Test Example 5] Estrogen-like action test Tenninka ground extract (Samples 1 to 3) obtained in Production Example 1, Tenninka root extract (Samples 4 to 6) obtained in Production Example 2 and Production Example 3 About the obtained tenninka fruit part extract (samples 7-9), the estrogen-like action was tested as follows.
ヒト乳癌由来細胞（ＭＣＦ−７）を１０％ＦＢＳ、１％ＮＥＡＡ及び１ｍｍｏｌ／Ｌのピルビン酸ナトリウムを含有するＭＥＭ培地を用いて培養した後、トリプシン処理により細胞を回収した。回収した細胞を、活性炭処理した１０％ＦＢＳ、１％ＮＥＡＡ及び１ｍｍｏｌ／Ｌのピルビン酸ナトリウムを含有しフェノールレッドを含有しないＭＥＭ培地（Ｔ−ＭＥＭ培地）を用いて、３．０×１０４ｃｅｌｌｓ／ｍＬの細胞密度に調整した後、４８ウェルプレートに１ウェルあたり４５０μＬずつ播種し、細胞を定着させるため培養した。６時間後（０日目）にＴ−ＭＥＭ培地で終濃度の１０倍に調整した試料溶液（試料濃度：１２．５μｇ／ｍＬ）を各ウェルに５０μＬずつ添加し培養を続けた。３日目に培地を抜き、Ｔ−ＭＥＭ培地で終濃度に調整した試料溶液を各ウェルに０．５ｍＬずつ添加し、さらに培養を続けた。 Human breast cancer-derived cells (MCF-7) were cultured in a MEM medium containing 10% FBS, 1% NEAA and 1 mmol / L sodium pyruvate, and then cells were collected by trypsin treatment. The recovered cells were treated with activated carbon-treated 10% FBS, 1% NEAA, and 1 mmol / L sodium pyruvate and no phenol red, and 3.0 × 10 4 cells using MEM medium (T-MEM medium). After adjusting to a cell density of / mL, the cells were seeded in a 48-well plate at 450 μL per well and cultured to establish the cells. Six hours later (day 0), 50 μL of a sample solution (sample concentration: 12.5 μg / mL) adjusted to 10 times the final concentration in T-MEM medium was added to each well, and the culture was continued. On the third day, the medium was removed, 0.5 mL of the sample solution adjusted to the final concentration with T-MEM medium was added to each well, and the culture was further continued.
エストロゲン様作用は、ＭＴＴアッセイ法を用いて測定した。培養終了後、培地を抜き、１％ＮＥＡＡ及び１ｍｍｏｌ／Ｌのピルビン酸ナトリウムを含有するＭＥＭ培地に終濃度０．４ｍｇ／ｍＬで溶解したＭＴＴを各ウェルに２００μＬずつ添加した。２時間培養した後に、細胞内に生成したブルーホルマザンを２−プロパノール２００μＬで抽出した。抽出後、波長５７０ｎｍにおける吸光度を測定した。同時に濁度として波長６５０ｎｍにおける吸光度を測定し、両者の差をもってブルーホルマザン生成量とした。ポジティブコントロールとして、１×１０−９Ｍのエストラジオールを使用した。得られた結果から、下記の式により、試料溶液添加時のエストロゲン様作用率（％）を算出した。 Estrogen-like effects were measured using the MTT assay. After completion of the culture, the medium was removed, and 200 μL of MTT dissolved in a final concentration of 0.4 mg / mL in MEM medium containing 1% NEAA and 1 mmol / L sodium pyruvate was added to each well. After culturing for 2 hours, blue formazan produced in the cells was extracted with 200 μL of 2-propanol. After extraction, the absorbance at a wavelength of 570 nm was measured. At the same time, the absorbance at a wavelength of 650 nm was measured as turbidity, and the difference between the two was used as the amount of blue formazan produced. As a positive control, 1 × 10 −9 M estradiol was used. From the obtained results, the estrogen-like action rate (%) at the time of adding the sample solution was calculated by the following formula.
エストロゲン様作用率(％)＝Ａ／Ｂ×１００
式中、Ａは試料溶液添加時の吸光度を表し、Ｂは試料溶液無添加時の吸光度を表す。
上記試験の結果を表８に示す。
Estrogen-like action rate (%) = A / B × 100
In the formula, A represents the absorbance when the sample solution was added, and B represents the absorbance when no sample solution was added.
The results of the above test are shown in Table 8.
［表８］
試 料 エストロゲン様作用率（％）
１ １１９．８
２ １３１．０
３ １２６．５
４ １２３．８
５ １２６．３
６ １２３．８
７ １０９．４
８ １２０．３
９ １１５．８
[Table 8]
Sample Estrogen-like action rate (%)
1 119.8
2 131.0
3 126.5
4 123.8
5 126.3
6 123.8
7 109.4
8 120.3
9 115.8
表８に示すように、テンニンカの地上部、根部及び果実部からの抽出物は、優れたエストロゲン様作用を有することが確認された。 As shown in Table 8, it was confirmed that extracts from the above-ground part, root part and fruit part of Tenninka have an excellent estrogenic action.
〔試験例６〕線維芽細胞増殖促進作用試験
製造例１で得られたテンニンカ地上部抽出物（試料１〜３）、製造例２で得られたテンニンカ根部抽出物（試料４〜６）及び製造例３で得られたテンニンカ果実部抽出物（試料７〜９）について、以下のようにして線維芽細胞増殖促進作用を試験した。
[Test Example 6] Fibroblast proliferation promoting action test Tenninka ground extract (Samples 1 to 3) obtained in Production Example 1, Tennin root extract (Samples 4 to 6) obtained in Production Example 2 and production About the Tenninka fruit part extract (samples 7-9) obtained in Example 3, the fibroblast proliferation promoting effect was tested as follows.
ヒト正常皮膚線維芽細胞（ＮＢ１ＲＧＢ）を１０％ＦＢＳ含有α−ＭＥＭを用いて培養した後、トリプシン処理により細胞を回収した。回収した細胞を７．０×１０４ｃｅｌｌｓ／ｍＬの濃度に５％ＦＢＳ含有α−ＭＥＭで希釈した後、９６ウェルプレートに１ウェルあたり１００μＬずつ播種し、一晩培養した。培養終了後、５％ＦＢＳ含有α−ＭＥＭで溶解した試料溶液（試料１〜３の試料濃度：５０μｇ／ｍＬ，試料４〜６の試料濃度：４００μｇ／ｍＬ，試料７の試料濃度：２００μｇ／ｍＬ，試料８の試料濃度：１００μｇ／ｍＬ，試料９の試料濃度：５０μｇ／ｍＬ）を各ウェルに１００μＬずつ添加し、３日間培養した。線維芽細胞増殖作用は、ＭＴＴアッセイ法を用いて測定した。培養終了後、各ウェルから１００μＬずつ培地を抜き、終濃度５ｍｇ／ｍＬでＰＢＳ（−）に溶解したＭＴＴを各ウェルに２０μＬずつ添加した。４．５時間培養した後に、１０％ＳＤＳを溶解した０．０１ｍｏｌ／Ｌの塩酸溶液を各ウェルに１００μＬずつ添加し、一晩培養した後、波長５７０ｎｍにおける吸光度を測定した。同時に濁度として波長６５０ｎｍにおける吸光度を測定し、両者の差をもってブルーホルマザン生成量とした。また、同様の方法で空試験を行い補正した。得られた結果から、下記の式により、線維芽細胞増殖促進率（％）を算出した。 Human normal skin fibroblasts (NB1RGB) were cultured using α-MEM containing 10% FBS, and then cells were collected by trypsin treatment. The collected cells were diluted with α-MEM containing 5% FBS to a concentration of 7.0 × 10 4 cells / mL, then seeded at 100 μL per well in a 96-well plate, and cultured overnight. After completion of the culture, a sample solution dissolved in α-MEM containing 5% FBS (sample concentration of samples 1 to 3: 50 μg / mL, sample concentration of samples 4 to 6: 400 μg / mL, sample concentration of sample 7: 200 μg / mL) , Sample concentration of sample 8: 100 μg / mL, sample concentration of sample 9: 50 μg / mL) was added to each well, and cultured for 3 days. Fibroblast proliferation was measured using the MTT assay. After completion of the culture, 100 μL of the medium was removed from each well, and 20 μL of MTT dissolved in PBS (−) at a final concentration of 5 mg / mL was added to each well. After culturing for 4.5 hours, 100 μL of a 0.01 mol / L hydrochloric acid solution in which 10% SDS was dissolved was added to each well and incubated overnight, and then the absorbance at a wavelength of 570 nm was measured. At the same time, the absorbance at a wavelength of 650 nm was measured as turbidity, and the difference between the two was used as the amount of blue formazan produced. In addition, a blank test was performed and corrected in the same manner. From the obtained results, the fibroblast proliferation promotion rate (%) was calculated by the following formula.
線維芽細胞増殖促進率(％)＝(Ｓｔ−Ｓｂ)／(Ｃｔ−Ｃｂ)×１００
式中、Ｓｔは試料を添加した細胞での吸光度を表し、Ｓｂは試料を添加した空試験の吸光度を表し、Ｃｔは試料を添加しない細胞での吸光度を表し、Ｃｂは試料を添加しない空試験の吸光度を表す。
上記試験の結果を表９に示す。
Fibroblast proliferation promotion rate (%) = (St−Sb) / (Ct−Cb) × 100
In the formula, St represents the absorbance in the cells to which the sample was added, Sb represents the absorbance in the blank test to which the sample was added, Ct represents the absorbance in the cells to which no sample was added, and Cb represents the blank test in which the sample was not added. Represents the absorbance.
Table 9 shows the results of the above test.
［表９］
試 料 線維芽細胞増殖促進率（％）
１ １０３．６
２ １１１．７
３ １２６．０
４ １１０．３
５ １２６．４
６ １２９．６
７ １０３．４
８ １２９．５
９ １３３．６
[Table 9]
Sample Fibroblast proliferation promotion rate (%)
1 103.6
2 111.7
3 126.0
4 110.3
5 126.4
6 129.6
7 103.4
8 129.5
9 133.6
表９に示すように、テンニンカの地上部、根部及び果実部からの抽出物は、優れた線維芽細胞増殖促進作用を有することが確認された。 As shown in Table 9, it was confirmed that the extracts from the above-ground part, root part, and fruit part of Tenninka have an excellent fibroblast proliferation promoting action.
〔試験例７〕サイクリックＡＭＰホスホジエステラーゼ阻害作用試験
製造例１で得られたテンニンカ地上部抽出物（試料１〜３）、製造例２で得られたテンニンカ根部抽出物（試料４〜６）及び製造例３で得られたテンニンカ果実部抽出物（試料７〜９）について、以下のようにしてサイクリックＡＭＰホスホジエステラーゼ阻害作用を試験した。
[Test Example 7] Cyclic AMP phosphodiesterase inhibitory action test Tenninka ground extract (Samples 1 to 3) obtained in Production Example 1, Tenninka root extract (Samples 4 to 6) obtained in Production Example 2 and production For the Tenninka fruit part extract (samples 7 to 9) obtained in Example 3, the cyclic AMP phosphodiesterase inhibitory action was tested as follows.
５ｍｍｏｌ／Ｌの塩化マグネシウムを含有する５０ｍｍｏｌ／Ｌのトリス塩酸緩衝液（ｐＨ７．５）０．２ｍＬに、２．５ｍｇ／ｍＬのウシ血清アルブミン溶液０．１ｍＬ、０．１ｍｇ／ｍＬのホスホジエステラーゼ溶液０．１ｍＬ及び試料溶液０．０５ｍＬを加え、３７℃で５分間予備反応させた。この反応溶液に、０．５ｍｇ／ｍＬのサイクリックＡＭＰ溶液０．０５ｍＬを加え、３７℃で６０分間反応させた。３分間沸騰水浴上で煮沸することにより反応を停止させ、これを遠心（３５００ｒｐｍ，４℃）し、上清中の反応基質である５’−ＡＭＰを、下記の条件で高速液体クロマトグラフィーを用いて分析した。また、試料溶液を添加せずに同様の方法で空試験を行った。 To 0.2 mL of 50 mmol / L Tris-HCl buffer (pH 7.5) containing 5 mmol / L magnesium chloride, 0.1 mL of a 2.5 mg / mL bovine serum albumin solution, 0.1 mg / mL phosphodiesterase solution 0 .1 mL and 0.05 mL of the sample solution were added and pre-reacted at 37 ° C. for 5 minutes. To this reaction solution, 0.05 mL of a 0.5 mg / mL cyclic AMP solution was added and reacted at 37 ° C. for 60 minutes. The reaction was stopped by boiling on a boiling water bath for 3 minutes, this was centrifuged (3500 rpm, 4 ° C.), and the reaction substrate 5′-AMP in the supernatant was subjected to high performance liquid chromatography under the following conditions. And analyzed. In addition, a blank test was performed in the same manner without adding the sample solution.
＜高速液体クロマトグラフィー条件＞
製品名：Chromatocorder 12（SYSTEM INSTRUMENTS社製）
固定相：Wakosil 5C18（和光純薬工業社製）
カラム径：４．６ｍｍ
カラム長：２５０ｍｍ
移動相：1mM TBAP in 25mM KH2PO4:CH3CN = 90:10
移動相流速：１．０ｍＬ／ｍｉｎ
検出：ＵＶ，２６０ｎｍ
<High performance liquid chromatography conditions>
Product name: Chromatocorder 12 (manufactured by SYSTEM INSTRUMENTS)
Stationary phase: Wakosil 5C 18 (Wako Pure Chemical Industries, Ltd.)
Column diameter: 4.6 mm
Column length: 250mm
Mobile phase: 1 mM TBAP in 25 mM KH 2 PO 4 : CH 3 CN = 90:10
Mobile phase flow rate: 1.0 mL / min
Detection: UV, 260nm
上記液体クロマトグラフィーによる分析結果であるサイクリックＡＭＰのピーク面積から、サイクリックＡＭＰホスホジエステラーゼ阻害率（％）を下記の式により算出した。 The cyclic AMP phosphodiesterase inhibition rate (%) was calculated from the following formula using the cyclic AMP peak area, which is the analysis result of the liquid chromatography.
阻害率(％)＝(１−Ａ／Ｂ)×１００
式中、Ａは試料溶液添加時のサイクリックＡＭＰのピーク面積を表し、ＢはコントロールのサイクリックＡＭＰのピーク面積を表す。
Inhibition rate (%) = (1−A / B) × 100
In the formula, A represents the peak area of cyclic AMP at the time of addition of the sample solution, and B represents the peak area of control cyclic AMP.
試料溶液の濃度を段階的に減少させて、上記サイクリックＡＭＰホスホジエステラーゼ阻害率（％）を算出し、サイクリックＡＭＰホスホジエステラーゼ阻害率が５０％になる試料濃度ＩＣ５０（μｇ／ｍＬ；ｐｐｍ）の値を内挿法により算出した。
上記試験の結果を表１０に示す。
The concentration of the sample solution is decreased stepwise to calculate the cyclic AMP phosphodiesterase inhibition rate (%), and the value of the sample concentration IC 50 (μg / mL; ppm) at which the cyclic AMP phosphodiesterase inhibition rate becomes 50%. Was calculated by interpolation.
The results of the above test are shown in Table 10.
［表１０］
試 料 ＩＣ ５０ （μｇ／ｍＬ）
１ １９５
２ ５７．６
３ ７５．５
４ ４５．１
５ ２０．５
６ １８５
７ ＞２００
８ ５５．２
９ ４７．６
[Table 10]
Sample IC 50 (μg / mL)
1 195
2 57.6
3 75.5
4 45.1
5 20.5
6 185
7> 200
8 55.2
9 47.6
表１０に示すように、テンニンカの地上部、根部及び果実部からの抽出物は、優れたサイクリックＡＭＰホスホジエステラーゼ阻害作用を有することが確認された。また、サイクリックＡＭＰホスホジエステラーゼ阻害作用の程度は、抽出物の濃度によって調節できることが確認された。 As shown in Table 10, it was confirmed that the extracts from the aerial part, root part and fruit part of Tenninka have an excellent cyclic AMP phosphodiesterase inhibitory action. It was also confirmed that the degree of cyclic AMP phosphodiesterase inhibitory action can be adjusted by the concentration of the extract.
〔配合例１〕
下記組成の乳液を常法により製造した。
テンニンカ根部水抽出物（製造例２） ０．０１ｇ
ホホバオイル ４．０ｇ
プラセンタエキス ０．１ｇ
カミツレエキス ０．１ｇ
オリーブオイル ２．０ｇ
スクワラン ２．０ｇ
セタノール ２．０ｇ
モノステアリン酸グリセリル ２．０ｇ
ポリオキシエチレンセチルエーテル（20E.O.） ２．５ｇ
オレイン酸ポリオキシエチレンソルビタン（20E.O.） ２．０ｇ
１，３−ブチレングリコール ３．０ｇ
ヒノキチオール ０．１５ｇ
香料 ０．０５ｇ
精製水 残部（全量を１００ｇとする）
[Formulation Example 1]
An emulsion having the following composition was produced by a conventional method.
Tenninka Root Water Extract (Production Example 2) 0.01 g
Jojoba oil 4.0g
Placenta extract 0.1g
Chamomile extract 0.1g
Olive oil 2.0g
Squalane 2.0g
Cetanol 2.0g
Glyceryl monostearate 2.0g
Polyoxyethylene cetyl ether (20E.O.) 2.5g
Oleic acid polyoxyethylene sorbitan (20E.O.) 2.0g
1,3-butylene glycol 3.0 g
Hinokitiol 0.15g
Fragrance 0.05g
Purified water remainder (total amount is 100 g)
〔配合例２〕
下記組成のクリームを常法により製造した。
テンニンカ地上部５０％エタノール抽出物（製造例１） ０．１ｇ
ニンジンエキス ０．１ｇ
ワレモコウエキス ０．１ｇ
流動パラフィン ５．０ｇ
サラシミツロウ ４．０ｇ
セタノール ３．０ｇ
スクワラン １０．０ｇ
ラノリン ２．０ｇ
ステアリン酸 １．０ｇ
オレイン酸ポリオキシエチレンソルビタン（20E.O.） １．５ｇ
モノステアリン酸グリセリル ３．０ｇ
１，３−ブチレングリコール ６．０ｇ
パラオキシ安息香酸メチル １．５ｇ
香料 ０．１ｇ
精製水 残部（全量を１００ｇとする）
[Formulation Example 2]
A cream having the following composition was produced by a conventional method.
Tenninka above ground 50% ethanol extract (Production Example 1) 0.1 g
Carrot extract 0.1g
Walnut extract 0.1g
Liquid paraffin 5.0g
Salami beeswax 4.0g
Cetanol 3.0g
Squalane 10.0g
Lanolin 2.0g
Stearic acid 1.0g
Oleic acid polyoxyethylene sorbitan (20E.O.) 1.5g
3.0 g glyceryl monostearate
1,3-butylene glycol 6.0 g
1.5 g of methyl paraoxybenzoate
Fragrance 0.1g
Purified water remainder (total amount is 100 g)
〔配合例３〕
下記組成のパックを常法により製造した。
テンニンカ地上部水抽出物（製造例１） ０．０５ｇ
アロエエキス ０．１ｇ
加水分解コンキオリン ０．１ｇ
ポリビニルアルコール １５ｇ
ポリエチレングリコール ３ｇ
プロピレングリコール ７ｇ
エタノール １０ｇ
パラオキシ安息香酸エチル ０．０５ｇ
香料 ０．０５ｇ
精製水 残部（全量を１００ｇとする）
[Composition Example 3]
A pack having the following composition was produced by a conventional method.
Tenninka above ground water extract (Production Example 1) 0.05 g
Aloe extract 0.1g
Hydrolyzed conchiolin 0.1g
Polyvinyl alcohol 15g
Polyethylene glycol 3g
7g of propylene glycol
Ethanol 10g
0.05 g ethyl paraoxybenzoate
Fragrance 0.05g
Purified water remainder (total amount is 100 g)
〔配合例４〕
下記組成の化粧水を常法により製造した。
テンニンカ果実部８０％エタノール抽出物（製造例３） ０．０５ｇ
グリチルリチン酸ジカリウム ０．１ｇ
油溶性甘草エキス ０．１ｇ
グリセリン ５．０ｇ
プロピレングリコール ５．０ｇ
ポリエチレングリコール ２．０ｇ
ポリオキシエチレンセチルエーテル ２．０ｇ
エタノール ７．０ｇ
水酸化カリウム ０．０１ｇ
香料 ０．０１ｇ
パラオキシ安息香酸ブチル ０．０５ｇ
水溶性色素 ０．２ｇ
精製水 残部（全量を１００ｇとする）
[Formulation Example 4]
A lotion having the following composition was produced by a conventional method.
Tenninka fruit part 80% ethanol extract (Production Example 3) 0.05 g
0.1g dipotassium glycyrrhizinate
Oil soluble licorice extract 0.1g
Glycerin 5.0g
Propylene glycol 5.0g
Polyethylene glycol 2.0g
Polyoxyethylene cetyl ether 2.0g
7.0g ethanol
Potassium hydroxide 0.01g
Fragrance 0.01g
Butyl paraoxybenzoate 0.05g
Water-soluble pigment 0.2g
Purified water remainder (total amount is 100 g)
本発明の抗炎症剤は、各種炎症性疾患の予防、治療又は改善に、本発明の美白剤又はチロシナーゼ阻害剤は、皮膚色素沈着症、シミ等の予防、治療又は改善に、本発明の抗老化剤は、皮膚の老化の予防、治療又は改善に、本発明のスリミング剤又はサイクリックＡＭＰホスホジエステラーゼ阻害剤は、肥満症の予防、治療又は改善に大きく貢献できる。
The anti-inflammatory agent of the present invention is used for the prevention, treatment or improvement of various inflammatory diseases, and the whitening agent or tyrosinase inhibitor of the present invention is used for the prevention, treatment or improvement of skin pigmentation, stains, etc. The aging agent can greatly contribute to the prevention, treatment or improvement of skin aging, and the slimming agent or cyclic AMP phosphodiesterase inhibitor of the present invention can greatly contribute to the prevention, treatment or improvement of obesity.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005352733A JP5512067B2 (en) | 2004-12-24 | 2005-12-06 | Skin cosmetics |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004373659 | 2004-12-24 | ||
| JP2004373659 | 2004-12-24 | ||
| JP2005352733A JP5512067B2 (en) | 2004-12-24 | 2005-12-06 | Skin cosmetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006199678A JP2006199678A (en) | 2006-08-03 |
| JP5512067B2 true JP5512067B2 (en) | 2014-06-04 |
Family
ID=36957994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005352733A Expired - Fee Related JP5512067B2 (en) | 2004-12-24 | 2005-12-06 | Skin cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5512067B2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4456585B2 (en) | 2006-09-06 | 2010-04-28 | 株式会社ノエビア | Cell activator, collagen production promoter, whitening agent, antioxidant, anti-inflammatory agent, aromatase activity promoter, protease activity promoter, topical skin preparation and food |
| JP2008285422A (en) * | 2007-05-15 | 2008-11-27 | Maruzen Pharmaceut Co Ltd | Dna damage inhibitor and glutathione production promoter |
| FR2930145B1 (en) * | 2008-04-16 | 2012-08-03 | Fabre Pierre Dermo Cosmetique | USE OF MYRT EXTRACT AS DEPIGMENTING. |
| JP2010150195A (en) * | 2008-12-25 | 2010-07-08 | Kao Corp | Dna-restoration promoting agent |
| JP5794839B2 (en) * | 2011-06-28 | 2015-10-14 | 花王株式会社 | Skin cosmetics |
| JP2013155141A (en) * | 2012-01-31 | 2013-08-15 | Mikimoto Pharmaceut Co Ltd | Cosmetic |
| FR3100455B1 (en) * | 2019-09-05 | 2022-02-18 | Clarins Lab | COSMETIC COMPOSITION COMPRISING AN EXTRACT OF RHODOMYRTUS TOMENTOSA FRUIT |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06293654A (en) * | 1993-04-02 | 1994-10-21 | Nippon Mektron Ltd | Active oxygen scavenging agent and aldose reductase inhibiting agent |
| JPH1036278A (en) * | 1996-07-19 | 1998-02-10 | Pola Chem Ind Inc | Agent for suppressing formation of lipid peroxide and composition containing the agent |
| CN1086583C (en) * | 1998-04-28 | 2002-06-26 | 王兴体 | Powder and pellet for strengening yang |
| FR2778105B1 (en) * | 1998-04-30 | 2000-07-28 | Hassan Halaby | PLANT EXTRACTS USED TO COMBAT HAIR LOSS AND THEIR PREPARATION |
| JP2001002574A (en) * | 1999-06-17 | 2001-01-09 | Shiseido Co Ltd | Accelerator for recovering skin barrier function |
| JP2003246746A (en) * | 2002-02-25 | 2003-09-02 | Kurabo Ind Ltd | Lipase inhibitor and processed food possessing lipase inhibitory activity |
-
2005
- 2005-12-06 JP JP2005352733A patent/JP5512067B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006199678A (en) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7390755B2 (en) | Skin cosmetics, hair cosmetics, food and beverages | |
| JP5224648B2 (en) | Anti-dermatitis agent, whitening agent and anti-skin aging agent | |
| JP2009046465A (en) | Skin cosmetic and food/drink | |
| JP6055667B2 (en) | Collagen production promoter | |
| JP5612267B2 (en) | Skin cosmetics | |
| KR101283849B1 (en) | Novel cosmetic composition having antioxidant activity and skin-whitening effect | |
| JP5512067B2 (en) | Skin cosmetics | |
| JP4672269B2 (en) | Anti-aging agent, platelet aggregation inhibitor, antioxidant, antiallergic agent, skin cosmetics and food and drink | |
| JP7598670B2 (en) | Skin cosmetics, hair cosmetics, and food and beverages | |
| KR20190064714A (en) | Anti-inflammatory agent containing backhousia citriodora extract | |
| JP5220346B2 (en) | Skin cosmetics | |
| JP7148115B2 (en) | Collagen production promoter, MMP inhibitor, melanogenesis inhibitor, cell proliferation promoter, antioxidant, wrinkle improving agent, pharmaceutical or food composition | |
| JP5300233B2 (en) | Skin cosmetics | |
| JP2006008571A (en) | Moisturizer, antioxidant, antiaging agent, skin cosmetic and beauty drink and food | |
| KR20200038114A (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
| JP5419258B2 (en) | Cosmetics | |
| KR102337346B1 (en) | Cosmetic composition containing extract of Pinus rigida Mill. for antioxidative or anti-aging | |
| KR102244585B1 (en) | Complex cosmetic composition for improving skin-aging | |
| JP4587755B2 (en) | Anti-inflammatory agent, whitening agent, anti-aging agent, and skin cosmetic | |
| JP5419259B2 (en) | Cosmetics | |
| JP7389465B2 (en) | Melanin production inhibitor, collagen production promoter and antioxidant | |
| JP2010105949A (en) | Skin cosmetic and food and drink | |
| JP2017075118A (en) | Skin whitening agent, anti-aging agent and functional food and drink | |
| KR20240165095A (en) | Composition for Improving Skin Conditions Comprising Extract of Cheongyang Pepper as Active Ingredient | |
| JP2024060053A (en) | Inhibitor for inhibiting moisture keeping function reduction caused by saccharization, skin cosmetic and food/drink |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120206 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120425 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140214 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140326 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5512067 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |